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1. Introduction 
1.1 Background to Research 
The AIDS epidemic has been identified as the primary public health concern of many 
developing countries. The social, economic and public health impacts ofHIV/AIDS continue 
to rise, and the links between the incidence of infection and the level of human and economic 
development are increasingly evident (Bourne: 2003). In order to attempt to limit the current 
and future economic and public health costs imposed by HIV/AIDS, a number of severely-
affected developing countries are in the process of introducing treatment programmes based 
on the use of antiretroviral drugs. 
South Africa is amongst the first of these severely-affected countries to implement a 
comprehensive antiretroviral-based treatment programme for persons infected with HIV. This 
treatment programme was officially introduced in April 2004 and aims to provide Highly 
Active Antiretroviral Therapy (HAART) to infected persons through the public health system 
and via non-governmental aid organisations. Antiretroviral treatment does not provide a cure 
for HIV/AIDS, but frequently results in a dramatic reduction in morbidity and mortality in 
infected individuals (Forsythe et al: 1999; Casseb et al: 2003). 
It is hoped that the widespread use of HAART will limit the negative economic and public 
health impacts of the AIDS epidemic. Whilst anticipated to reduce overall levels of HIV-
related hospital admissions, the widespread provision and use of antiretroviral drugs has the 
potential to create specific added burdens on the health system, and on secondary (or referral) 
hospitals in particular, as a result of high levels of morbidity and associated treatment costs in 
patients with advanced HIY infection in the early stages ofHAART, and in patients preparing 
to initiate HAART (Arens et al: 2004). Current public sectorguidelines on antiretro viral 
therapy focus on provision for patients at an advanced stage of infection] (National 
I HIV-positive patients presenting with CD4 counts below 200 cells,,"l] and/or WHO Clinical Stage 4 diagnosis. 
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Department of Health: 2004a), with a median CD4 count of 43 (n = 287) recorded at HAART 
initiation in Khayelitsha (Coetzee et al: 2004). 
Secondary hospitals face significant resource requirements for identifying the causes of 
morbidity in patients receiving HAART, including new opportunistic infections, paradoxical 
deterioration of pre-existing opportunistic infections, and drug side effects, and for pre-
HAART morbidity assessment (Meintjes: 2004b). In addition, the increased survival time of 
HAART patients has the potential to result in higher levels of demand for secondary hospital 
treatment over the life span. The incidence of these various treatment requirements can be 
expected to increase in proportion to the level and scale of the national HAART roll-out. In 
order to ensure that the health system is not overburdened in caring for patients on or 
preparing for HAART, the need for a specific service arm devoted to their treatment has been 
proposed. 
1.2 Problem Statement 
The widespread use of HAART has the potential to create an increased demand for certain 
specific treatment requirements provided by secondary hospitals. Most patients commencing 
HAART in disadvantaged areas are at a stage of advanced immunosuppression (Coetzee et al: 
2004). These patients remain immunosuppressed while preparing for (or during the initial 
period of) HAART treatment, and may continue to develop opportunistic infections or 
Immune Reconstitution Syndrome during this time. The development of specific treatment 
services will improve secondary level care for patients on or preparing for HAART and 
ensure earlier treatment upon development of medical problems. 'This in tum will prevent 
the deterioration and ultimately prolonged hospitalisation that many of these patients require' 
(Meintjes: 2004b, p 4). 
The development of Antiretroviral Referral Units, specifically designed for the assessment 
and treatment of patients on or preparing for HAART, as well as the expansion of associated 
secondary hospital services, should be included as a key element of the planning of the 
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national antiretroviral roll-out in order to avoid excessive strain on the South African health 
system. Using a combination of current and retrospective data from OF Jooste Secondary 
Hospital. this study provides a comprehensive cost analysis, a cost-outcome description and a 
prospective costing model for the implementation of a proposed Antiretroviral Referral Unit, 
which may be used as a template for similar units in other secondary hospitals in South 
Africa. A range of descriptive and epidemiological data sets are also presented in order to 
provide a detailed assessment of the characteristics and treatment needs ofHAART patients at 
the secondary level. 
1.3 Study Area and Setting 
1.3.1 GF Jooste Hospital 
All research for this study was conducted at OF Jooste Hospital, located in Manenberg, Cape 
Town, in the Western Cape Province of South Africa. OF Jooste Hospital is a public sector 
secondary hospital serving the Klipfontein Health District and is administered by the 
Provincial Government of the Western Cape. The hospital was established in 1975 as an 
inpatient convalescent care centre. Trauma and emergency services have been provided since 
1996 and an outpatient department was opened in 2001. An infectious disease clinic and an 
antiretroviral clinic were established in the hospital in 2003. In addition, OF Jooste Hospital 
provides secondary treatment and referral facilities for the antiretroviral clinics located within 
its Catchment Area at Mitchell's Plain, Guguletu, Crossroads, Site B and Site C (Nolungile 
Clinici. 
2 Patients resident in the GF ]ooste Catchment Area and attending the Red Cross (for parents of infected children) 
or Groote Schuur Antiretroviral Clinics are also occasionally referred to the Antiretroviral Referral Unit. 
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1.3.2 Catchment Area 
GF Jooste Hospital serves a population of approximately 1.2 million people (Meintjes: 
2004a). The GF Jooste Catchment Area includes the areas of North Khayelitsha, Nyanga, 
Guguletu, Mitchells Plain, Heideveld, Crossroads, Manenberg, Strandfontein and Phillipi. 
These areas include some of the most socially and economically disadvantaged communities 
in the Western Cape Province. . The broad unemployment rate in the Khayelitsha and 
Mitchells Plain areas has been estimated at 46.3%3 (Nattrass: 2003). The area of Manenberg 
has been described as 'an established African working class township' (Govender et at: 2000, 
p 11). Housing is composed of a combination of informal shacks, council houses, and private 
houses. HIV prevalence in the Catchment Area is estimated at 10.7% (Human Sciences 
Research Council: 2004) or 120,000 persons (Meintjes: 2004a). Access to private health care 
is limited. 
1.4 The GF Jooste Antiretroviral Referral Unit 
1.4.1 Background to the Antiretroviral Referral Unit 
The GF Jooste Antiretroviral Referral Unit was established in August 2004. In response to a 
high level of casualty admissions for persons on HAART, the unit was initially designed to 
relieve demand on the Trauma and Emergency Department at GF Jooste Hospital. Significant 
and sustained levels of demand for secondary treatment by HIV / AIDS patients on or 
preparing for HAART prompted the expansion of the Antiretroviral Referral Unit into an 
independent clinical service, providing specialised medical treatment and expert medical 
opinion. The unit manages a wide range Qf HAART-related illnesses, including immune 
reconstitution syndrome, smear-negative tuberculosis treatment, hyperlactataemia, lactic 
acidosis, and other side-effects of antiretroviral drug use. 
3 The broad unemployment rate = (active-searching unemployed + network-searching unemployed + marginalized 
unemployed) I broad labour force. 
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The Antiretroviral Referral Unit provides inpatient and outpatient care for HAART patients. 
Outpatient care is currently provided through the GF Jooste Outpatient Department and 
Infectious Disease Clinic. Clinic hours are 8.00 am to 5.00 pm Monday to Friday, with a 
range of 5 to 15 patients seen on a daily basis. Consultations take place in outpatient 
department facilities and require the ad hoc use of consultation rooms in the absence of any 
designated physical infrastructure. Spatial limitations have been noted to severely hamper 
service provision (Meintjes: 2004a). 
Antiretroviral Referral Unit inpatient care is provided via the GF Jooste Inpatient Medical 
Ward. Inpatients are primarily managed by medical ward clinical staff, with additional 
specialist medical input supplied by Antiretroviral Referral Unit clinicians. Approximately 
40% of Antiretroviral Referral Unit outpatients subsequently require inpatient care (Meintjes: 
2004a). A telephone consultation service for local antiretroviral clinics is also provided by 
the unit, which is currently staffed by two (part-time) consultant HN / AIDS specialists, two 
medical officers, one (part-time) registered nurse, and an admissions clerk. 
1.4.2 Admission Procedure and Referral Chain 
Prospective Antiretroviral Referral Unit patients are discussed by telephone consultation with 
the attending primary antiretroviral clinic. Patients are then triaged to (1) immediate inpatient 
admission through GF Jooste Casualty, (2) an outpatient appointment at the Antiretroviral 
Referral Unit, or (3) continued primary care with specialist telephone assistance. Patients 
requiring an outpatient appointment are generally seen by clinicians within 48 hours of the 
initial telephone consultation (Meintjes: 2004a). These patients report to the GF Jooste 
Outpatient Department Reception and a patient file is opened. Patients are then evaluated by 
the attending Antiretroviral Referral Unit clinician(s), and an investigation and management 
plan is developed. 
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1.5 Proposed Antiretroviral Referral Unit 
Based on the consistent levels of prior demand for specialised secondary level services, and in 
anticipation of increasing demand for secondary hospital treatment of HAART patients with 
expansion of the antiretroviral roll-out, the establishment of an independent Antiretroviral 
Referral Unit at GF Jooste Hospital has been proposed. This initiative requires an 
independent building and specialist equipment in addition to existing resources. The 
proposed Antiretroviral Referral Unit will operate independently from the GF Jooste 
Outpatient Department and Infectious Disease Clinic. 
The proposed Antiretroviral Referral Unit will contain outpatient consulting rooms, a 
procedure room, a sluice room, staff offices and ablution facilities, and will be located within 
the grounds of GF Jooste Hospital. Key investigational equipment includes a CT scanner, 
gastro-intestinal scope facilities, bronchoscopy facilities and liver biopsy equipment. The 
proposed unit will employ existing clinical and non-clinical staff. The facility will also act as 
a training site for medical professionals in HIV medicine, and as a centre for local clinical 
research on key issues related to the antiretroviral roll-out. 
The proposed Antiretroviral Referral Unit will function primarily as an outpatient service. 
Inpatient care will continue to be provided by clinical staff at the GF Jooste Inpatient Medical 
Ward, supplemented by input from Antiretroviral Referral Unit clinicians. A range of 
medical and surgical procedures, examinations, imaging and radiology scanning, and 
laboratory testing for both inpatients and outpatients will be conducted at the Antiretroviral 
Referral Unit. 
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2. Literature Review 
2.1 Literature Sources 
This literature review was primarily conducted through a series of manual and electronic 
searches for relevant articles. The core electronic databases used to conduct this review were 
MedLine and PubMed. The words and phrases 'HIV/AIDS', 'Antiretrovirals', 'Cost 
Analysis', 'Complications', 'South Africa', 'Hospital' and 'Referrals', amongst other terms, 
were used in various combinations to search these databases. A similar literature search was 
conducted through the ALEPH database of the University of Cape Town. 
A number of reviewed articles were provided by members of staff at the Health Economics 
Unit in the Department of Public Health, University of Cape Town. Consultation with 
academics and professionals working in the fields of public health and health economics in 
other institutions via e-mail also rendered a number of relevant documents. Literature 
searches were also conducted through the internet. Relevant references in articles found 
through all ofthese sources were used as an ad hoc literature source. 
All literature available from GF Jooste Hospital relating to the proposed Antiretroviral 
Referral Unit was reviewed for this proposal. This included a comprehensive business plan 
(Meintjes: 2004a), internal correspondence outlining the rationale for Antiretroviral Referral 
Unit construction (Meintjes: 2004b), and a presentation describing the key elements of service 
provision required to treat patients on HAART at the secondary level (Meintjes: 2004c). 
These documents provided a key source of background information on the structure, 
requirements and demand for the Antiretroviral Referral Unit. 
2.2 Economic Evaluation in the Health Care Setting 
A review of economic evaluation studies in health care was conducted to provide a general 
framework for this research. An assessment of the demand for economic evaluation studies in 
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health care provided a key motivation for this study. ill addition, a selected review of the 
application of economic evaluation in specific health care scenarios provided' valuable 
insights into key techniques and procedures. 
2.2.1 Demand for Economic Evaluation in Health Care 
ill his study ofthe cost-effectiveness ofHIV/AIDS prevention strategies, Walker (2003) states 
that there is 'an urgent need for the generation of this knowledge for planning and decision-
making' (p 4). A wide range of HI VIA IDS interventions in developing countries are shown 
to lack an evaluative basis, raising questions about their appropriateness. For those 
interventions that have been evaluated, the frequent incomparability of methods and results is 
compounded by the lack of a common outcome measure. The analysis of epidemics in 
developing countries requires 'better definition and cost analysis of the new interventions or 
strategies needed to facilitate improved levels of control' (Floyd et al: 2003, p 5). 
2.2.2 Application of Economic Evaluation in Health Care 
ill their study of hospital efficiency, Kirigia et al (1998) undertake a comparative cost-
effectiveness analysis between two Kenyan hospitals for a malaria-related intervention. This 
study presents a detailed description of data sourcing and record review procedures in a 
developing country hospital, which informed data collection methodology. These procedures 
include the timeframe for data collection at the hospital level, the cross-checking of medical 
records with other data sources, and key sources of data within the hospital system. 
ill their costing study of tuberculosis care in Cape Town, Sinanovic et al (2003) provide a 
detailed description of the procedures involved in community-based research, and present a 
comprehensive listing of provider costing centres. Key research issues include the 
identification of information sources within and outside the hospital, as well as the 
development of outcome measures appropriate to available data. Similarly, Chrischilles and 
Scholz (1999) describe the necessary techniques for the application of cost analysis to 
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hospital-based interventions, and outline alternative approaches for data collection. These 
include the categorisation of patient costs, the identification of hidden costs, and the 
establishment of costing boundaries. 
2.3 Economic Evaluation of Antiretroviral Programmes 
A wide range of recent studies attempt to assess the costs and effectiveness of HAART in 
developing countries. These studies emphasise the importance of the use of economic 
evaluation in antiretroviral-related interventions, provide detailed information on appropriate 
costing techniques, and illustrate gaps in the assessment of the health system impact of 
antiretroviral therapy. This research provided a basis for the economic evaluation of 
secondary level care for HAART patients. 
2.3.1 Cost Analysis of Antiretroviral Programmes 
The Health Systems Trust (2003) provides a comprehensive discussion of costing techniques 
for antiretroviral treatment programmes. An evaluation framework for assessing the 
investment required for construction and maintenance of an antiretroviral clinic is outlined, 
and all key primary level costs are identified. The roles of eligibility criteria, clinical 
guidelines and patient registration in providing efficient and effective treatment are discussed. 
The need for close co-ordination between all health service levels is observed as being critical 
to the effectiveness of widespread antiretroviral provision. 
Bekker et al (2003) provide a comprehensive retrospective financial analysis of a community-
based antiretroviral therapy clinic in South Africa based on pilot data from the Guguletu 
Community Health Centre. Data on service utilisation and resource consumption reflect a 
high potential demand for antiretroviral therapy, and indicate advanced immunosuppression in 
a high proportion of patients. In common with research on the costs of an Antiretroviral 
Referral Unit, the study focused on 'an easily replicable service delivery model' (p 459) with 
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the aim of 'facilitating expansion of this or similar service delivery models for antiretroviral 
therapy elsewhere in South Africa' (ibid). 
Beck et at (2001) present a comprehensive global systematic review of studies on the cost of 
HIV treatment and care, including antiretroviral therapy. The costs of adult hospital care for 
AIDS patients are estimated for the time periods pre-l 987, 1987-1995, and post-l 996. These 
costs are seen to stabilise after initial increases, in the context of rising costs for the treatment 
of asymptomatic patients. The authors note that inaccessibility of data is a key limitation to 
the generation of accurate treatment cost estimates. The need for improved relevant costing 
information, especially in non-industrialised countries, is again emphasised. 
2.3.2 Cost-Effectiveness Analyses of Antiretroviral Programmes 
Creese et at (2002) provide a detailed systematic review of evidence on the cost-effectiveness 
of HIV / AIDS interventions in· Africa. 24 studies were reviewed to calculate standardised 
estimates of the cost per HIV infection prevented and per disability-adjusted life year (DAL Y) 
gained for 31 different treatment interventions. Cost-outcome ratios were observed to vary 
widely across interventions, with preventive measures and tuberculosis treatment amongst the 
most cost-effective interventions. The role of antiretroviral drugs was recognised as critical to 
attaining the correct balance of prevention, treatment and care interventions. 
Moore and Bartlett's (1996) economic analysis of the use of combination antiretroviral 
therapy in HIV infection models the costs of care for HIV / AIDS patients in the United States. 
Projections of the estimated cumulative cost of care are presented along with morbidity and 
mortality estimates for intervention and non-intervention scenarios, the results supporting the 
use of HAART under appropriate circumstances. The study 'did not take into account the 
indirect costs associated with the increased duration of asymptomatic disease and improved 
life expectancy' (p 111) for patients on HAART. 
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Anis et al (2000) calculate the incremental costs of a range of alternative antiretroviral 
regimens in a Canadian hospital via a patient perspective. Data on patient-specific costs and 
outcomes was gathered from a longitudinal cohort of HIV -positive males over a period of 30 
months. The cost-effectiveness of antiretroviral use is shown to be within the range of 
therapy costs for comparable chronic diseases. 
In their cost-effectiveness study of antiretroviral treatment in a South African township, 
Cleary et al (2004a) outline the key overhead and patient-specific cost categories associated 
with antiretroviral treatment in South Africa. These include laboratory testing, primary and 
secondary prophylaxis, and phannaceutical expenditure. Examples of the categorisation of 
staffing and capital requirements are also provided. Bavry and Maudlin (1996) supplement 
these categories by providing a breakdown of costs associated with an outpatient AIDS clinic 
in the United States. 
2.4 Macroeconomic Costs of Antiretroviral Provision 
A number of macroeconomic costing and resource requirements studies for comprehensive 
HIV/AIDS treatment programmes in developing countries were reviewed. These studies are 
designed to provide a basis for healthcare resource planning (Beck et al: 2001), although 
estimates of programme costs were frequently observed to focus on the direct costs of 
antiretroviral medication, excluding or overlooking the required secondary and support costs 
(Hogg et al: 1998). Beck et al (2001) note that 'adequate research effort should be directed to 
improving the scope and quality of infonnation on costs of HIV service provision around the 
world' (p 14). Similarly, Forsythe and Gilks (1999) note that resources required for provision 
of ARV therapy beyond phannaceutical costs are significant and that 'it remains imperative to 
assess the full economic implications of offering antiretrovirals' (p 2). 
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2.4.1 World Health Organisation Estimates 
In their seminal discussion of antiretroviral provision costs, the WHO provides projected 
expenditure estimates for the '3 by 5' treatment goal, which aims to provide 3 million people 
in low and middle income countries with HAART by the end of 2005 (WHO: 2003). Data on 
HIV I AIDS incidence and treatment needs from the 34 countries which make up 90% of 
global demand for antiretroviral therapy were used to estimate the financial costs of a 
comprehensive multinational treatment and care programme. The report emphasises the 
importance of support cost inclusion (Gutierrez et al: 2004), and the cost of support activities 
is estimated at 12.2% of total projected expenditure. 
2.4.2 United Nations Estimates 
Schwartlander et al (2001) support these findings in their assessment of the resources required 
for HIV I AIDS treatment, prevention and care required to meet the UN Millennium Summit 
Goals. The costs of key interventions are estimated for 135 low and middle income countries, 
on the basis of projected HAART coverage across six global regions. Resource requirements 
are divided into expenditure on (1) prevention interventions and (2) care and support 
interventions. Programme costs of US$9.2 billion are projected for end-200S, with the share 
required for HAART increasing from 12.5% in 2002 to 26.0% in 2005, illustrating the 
increasing importance of antiretroviral therapy in planning estimates. 
Bertozzi et al (2004) present updated United Nations estimates of the resource needs for 
HIV I AIDS health care services in low and middle income countries. Prospective costs were 
estimated based on existing annual expenditure for HIV/AIDS health care activities in 
countries with a per capita gross national income level below US$926S. Total resource needs 
are estimated by multiplying the projected total number of persons utilising specific health 
services by the unit cost of providing that service. The authors note that 'a number of 
interventions identified as key elements in HIV care were not included in the model' (p 192), 
given the very limited cost data available for these programmes. 
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2.4.3 Commission on Macroeconomics and Health Estimates 
In their study of the costs required for expanding Tuberculosis, Malaria and HIV I AIDS 
treatment and care in Sub-Saharan Africa for the Commission on Macroeconomics and 
Health, Kumaranayake et at (2001) attempt to 'estimate the volume of additional resources 
that would be required for a large-scale expansion of activities' (p 1) and provide incremental 
HAART coverage costs for 2007 and 2015. Future expenditure levels are categorised 
according to implementation, investment, and management and administration of treatment 
programmes. By 2007, HAART costs are expected to range from US$3.0 billion to US$4.9 
billion, based on a target coverage level of 62.0%. Total expenditure on HIV/AIDS care, 
including the clinical management and prevention of opportunistic illnesses, is expected to 
require US$6.9 billion to US$12.0 billion at the same date. 
2.5 Guidelines for Large-Scale Antiretroviral Provision 
A review of key domestic and international guidelines for large-scale antiretroviral provision 
was conducted to determine the planning provisions for the secondary level treatment of 
HAART patients. The identification of key directives provides a framework for the 
development of specialised secondary level services. 
2.5.1 South African Guidelines 
The framework provided by the South African National Department of Health (2003) on 
AIDS treatment mechanisms outlines the key organisational and logistical elements of the 
national antiretroviral roll-out. These include prospective treatment and coverage levels, as 
well as a detailed assessment of the facilities and infrastructure required for HAART 
provision. The complications associated with the use of antiretroviral drugs are identified as 
requiring both a supportive environment and close ongoing monitoring (National Department 
of Health: 2003). 
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2.5.2 World Health Organisation Guidelines 
The World Health Organisation (2003) provides a broad description of the essential technical 
and operational aspects of a large-scale antiretroviral treatment programme in resource-poor 
settings. Guidelines on the extent of infrastructural and secondary health system support 
required for the successful widespread utilisation of HAART are included. Recommendation 
2.4 calls for the development of chronic care capacity in health facilities concurrent with the 
introduction of antiretroviral therapy, and states that district level hospitals must prepare for 
'the management of severe conditions of referred patients, including hospital admission where 
necessary' (p 23). 
2.5.3 Health Systems Trust Guidelines 
The Health Systems Trust (2004) provides a broad description of the resources required for 
large-scale antiretroviral provision and notes that adequate financial allocations are 
fundamental to programme success. The importance of a comprehensive approach to service 
delivery is emphasised, and potential key determinants of the success of the roll-out are 
identified. These include adequate staffing, strong programme management, ongoing 
evaluation of the HAART roll-out at all levels of delivery, and provision of HAART beyond 
well-resourced demographic centres. The need to monitor budgetary allocations to ensure 
that funding is spent effectively underlines the importance of utilising economic and cost 
analyses throughout the roll-out process, and at all levels of care. 
Barron (2003) describes the primary obstacles to the widespread provision of antiretrovirals, 
and notes that the improvement of the health service infrastructure to ensure adequate delivery 
of HAART is a key limiting constraint. The prioritisation of key support services highlights 
the importance of adequate preparation at the secondary hospital level for the successful 
nationwide introduction of antiretroviral treatment. Similarly, in their overview of the 
essential principles of widespread antiretroviral use, Schneider and Coetzee note that 
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'universal access to ART will require a new level of performance of our health system, 
necessitating an innovative approach to implementation' (p 772). 
2.5.4 Other Guidelines 
Guidelines for antiretroviral programmes in developing countries were supplemented by a 
review of the process of building comprehensive HIV I AIDS care services in the USA 
(Meredith et al: 1998). The study compares three major HIV service delivery models and 
describes their implementation and operation within different target populations. The 
provision of comprehensive integrated services for persons receiving HAART, including 
medical care case management and social support, is identified as key to successful treatment 
provision across all models4• 
2.6 Medical Treatment for HAART Patients 
A number of articles focusing on medical treatment for HAART patients and the clinical 
complications of antiretroviral drugs were reviewed. These articles helped inform the design 
of, and resource requirements for, appropriate secondary hospital services. 
2.6.1 Clinical Complications of Antiretroviral Therapy 
Stenzel and Carpenter (2000) provide a detailed scientific description of the management of 
the clinical complications of antiretroviral therapy based on their observation of adverse drug 
reactions and drug-related toxicities. Diagnosis of the most frequent and severe forms of 
complications is outlined. Havlir and Currier (2003) present a comprehensive list of the 
various major and minor metabolic complications that may arise as a result of HAART and 
provide guidelines on their frequency and incidence. These include cardiovascular risk, lipid 
disorders and lipoatrophy, renal complications, hepatic complications, tuberculosis, and other 
bacterial infections. 
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Edelstein and Wilson (2001) describe a strong correlation between errors in antiretroviral 
medication provision during secondary level hospitalisation based on a retrospective review 
of HIY -seropositive patients from 1998 to 2000. A review of inaccuracies in initial orders for 
medication, including errors in dosing intervals (100.0%) and dosing amounts (41.0%), 
indicates the importance of a coherent, efficient and specialist-based secondary level 
treatment system for HAART patients. 
2.6.2 Treatment of Clinical Complications 
Meintjes(2004b) provides a broad categorisation of the most common forms of medical 
treatment provided to patients on or preparing for HAART at GF Jooste Hospital. 
Information on the associated medical equipment and infrastructural requirements is also 
provided. The National Department of Health (2004b) presents a guide to the clinical 
treatment of side effects and drug interactions associated with HAART use as part of the 
Pharmacovigilance Programme. 
2.7 The Impact of HAART on Secondary Hospitals 
Studies on the effects of widespread HAART provision on secondary hospitals were reviewed 
to inform prospective demand for secondary level services in South Africa. In the absence of 
appropriate data from non-industrialised countries, empirical findings from developed 
countries with established large-scale antiretroviral programmes were considered in this 
reVIew. 
2.7.1 Hospital Admission and Expenditure Patterns 
A review of the impact of widespread HAART treatment on hospital services tended to 
describe a decline in the overall burden of care at the secondary level. Le Pen et al (2001) 
4 Resource constraints may limit the applicability ofthese findings in developing countries. 
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utilised a Markov Modelling procedure for data from 500 HAART patients in France to 
compute overall health system expenditure. The authors state that 'important savings in 
hospital charges can compensate for the extra cost associated with the initiation of HAART' 
(p 136). Similarly, a study of the general mortality and morbidity spectrum in Spain 
concluded that 'in the HAART era, hospital admissions and mortality due to AIDS-defining 
illnesses continue to decrease' (Esc olano Hortelano et al: 2004, p 5). 
2.7.2 Immunosuppression and Hospital Utilisation Levels 
Demand for secondary hospital services by patients on HAART was frequently observed to 
increase in proportion to the level of clinical advancement of HN / AIDS. In their study of the 
utilisation of hospital services by HN-infected children on HAART, Mandalia et al (1999) 
observed that 'when the data were analysed by the stage of HN infection, we found that the 
use of hospital services increased with disease severity' (p 2591). In the South African 
context, a high proportion of HAART patients are expected to initiate treatment with low 
CD4 levels (Coetzee et al: 2004; Meintjes: 2004a), imposing significant prospective demand 
on secondary hospital services. 
The cost of treatment of HAART patients at the secondary level has also been observed to 
increase with disease advancement. In France, Yazdanpanah et al (2002) stratified the 
lifetime cost of HAART patients by CD4 count and concluded that 'the cost of HN disease 
varies widely depending on the stage of illness' (p 266). In Japan, the cost of inpatient 
treatment ofHAART patients with low CD4 counts «50 cells/Jll) was 4.59 times higher than 
for patients with high CD4 counts (200 - 499 cells/Jll) (Kimura: 2002). In the United States, 
patients with a CD4 count of less that 200 cells/JlI recorded more than double the monthly 
hospital costs of patients with CD4 counts above this level (Moore and Bartlett: 1996). 
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2.8 Supplementary and Contextual Articles 
A number of supplementary and contextual articles relating to the AIDS epidemic in Africa 
were reviewed to provide background infonnation for this research. An understanding of the 
progress and broader effects of the AIDS epidemic in developing countries may assist in the 
creation of appropriate and cost-effective health system interventions. 
2.8.1 Progress of the AIDS Epidemic 
Bourne (2003) provides a detailed description of the retrospective and prospective progress of 
the AIDS epidemic in South Africa. Levels of HIV prevalence are expected to decline 
independent of planned interventions, although at a decreased rate. HIV/AIDS-related 
mortality in South Africa is not expected to peak until 2009. In addition, the widespread use 
of antiretroviral therapy is expected to produce a paradoxical rise in the HIV -positive 
population due to delay of death. The quality and scope of existing datasets on HIV I AIDS 
prevalence and other key demographic indicators are identified as limiting the development of 
appropriate health system responses. 
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2.8.2 Microeconomic Effects of HIV I AIDS 
Analysis of the direct costs of HIV I AIDS to South African industry is may be based on an 
aggregation of meso-level results. Morris and Cheevers' (2000) study of the effects of 
HIV/AIDS on a sugar mill and 'confirms the significant amount of lost economic activity due 
to HIV infection' (p 8), while presenting a compelling illustration of the microeconomic 
impact ofHIV/AIDS. Costs to small industry are divided between replacement worker costs, 
productivity losses and absenteeism. The ability to defer or avoid these costs through 
antiretroviral provision is considered a cost-effective response in this context. 
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3. Conceptual Framework 
This study calculates the economic fixed and variable costs and a cost-outcome description of 
the GF Jooste Antiretroviral Referral Unit from the provider perspective, using a combination 
of gross and micro full costing techniques. The following review of the accepted (and 
alternative) theoretical and applied economic evaluation procedures for the assessment of 
health care interventions provides a framework for this research methodology. 
3.1 Key Theoretical Concepts 
3.1.1 Study Design 
A partial economic evaluation occurs when 'both outcomes and costs of a single service or 
programme are described' (Drummond et al: 1988, p 8), In contrast, a full economic 
evaluation considers situations in which two or more alternatives are compared (ibid). In the 
absence of any identifiable parallel initiatives in this area of research, this study undertakes a 
partial economic evaluation through cost analysis, cost-outcome and cost projection 
components. 
Cost analysis involves 'the identification, measurement and valuation of all resource changes 
that occur as a specific health care intervention is implemented' (Drummond et al: 200 I, P 
68) and 'seeks to improve efficiency by guiding policy makers in how scarce resources can be 
used' (Hutubessy: 2002, p 89). A cost-outcome description is designed to attribute relevant 
costs to relevant effects by using health outcomes as the measure of effect (Drummond et al: 
2001). Cost projections are used to identify future needs, establish priorities, and set 
appropriate productivity and expenditure targets (Creese and Parker: 1994). 
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3.1.2 Costing Perspective 
A provider perspective is utilised in this study. This estimates all costs associated with the 
provision of an Antiretroviral Referral Unit as accounted for by the service provider 
(Drummond et al: 2001). The alternative societal or patient perspective study designs 
enumerate a wider range of productivity, time, indirect and intangible costs (ibid). Few 
studies calculate the costs associated with the latter perspectives because of difficulties in data 
collection (Beck et al: 2001; Sinanovic et al: 2003). Similarly, the use of a patient 
perspective poses difficulties in the measurement of intangible costs, such as the value of 
patient time. 
3.1.3 Financial and Economic Costs 
The results of this study are presented in the form of economic costs. While financial costs 
are limited to recorded monetary expenditure by providers, economic costs includes 'the cost 
of resources that were not regarded as costs to the health facility' (Govender et al: 2000, p 9) 
including external funding, the use of external facilities, and resource donations. Economic 
costs include a range of opportunity costs, which reflect the true societal valuation of the 
sacrificed resources (Drummond et al: 2001). All possible opportunity costs are not 
considered in this study as the 'accurate estimation of [such] costs is likely to be, in practice, 
an unrealistic objective' (Govender et al: 2000, p 16). 
3.1.4 Capital and Recurrent Costs 
Capital costs include all cost items with a lifespan of greater than one year (Creese and 
Parker: 1994). Recurrent costs include all cost items which require recurrent or ongoing 
expenditure, including personnel and overhead costs (ibid). 
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3.1.5 Fixed and Variable Costs 
Fixed costs are defined as all costs which 'do not change when the quantity of patient care 
changes' (Shepard et al: 2000, p 32). Fixed costs generally include a range of capital and 
other costs. Variable costs are defined as all costs which vary according to the quantity of 
outpatient visits or inpatient days (ibid). 
3.1.6 Full and Incremental Cost Analyses 
This study employs a full cost analysis technique. A full cost analysis quantifies all existing 
resources utilised to provide a service or intervention and is based on average prices. 
, Average prices include fixed costs, such as costs of hospital buildings and costs of 
overheads, as well as variable costs' (Drummond et al: 2001, p 71). An incremental cost 
analysis is limited to the additional or incremental resources used in the expansion of a service 
or intervention (ibid). 
3.2 Key Applied Concepts 
3.2.1 Gross and Micro Costing Techniques 
This research employs a combination of gross (step-down) and micro (ingredients-based) 
costing methods for the valuation of resource use. Gross costing occurs when 'total 
expenditure on a service is divided by the number of persons served over a particular time 
period to arrive at a per-person cost estimate for treatment over that period' (Beck et al: 2001, 
p 16). Conversely, micro costing focuses on the collection and analysis of resource inputs at 
the individual level and relates use of services to patient characteristics for the calculation of 
patient-specific costs (ibid). 
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3.2.2 Allocation Procedures 
This study employs a range of allocation procedures for the assignment of shared costs across 
inpatient and outpatient care. Allocation procedures are designed to ensure the appropriate 
distribution of costs across cost centres (Drummond et al: 2001) whereby 'all costs incurred 
in the provision of services are allocated to relevant services based on methods suitable for 
each category' (Matsheke: 2004, p 30). The allocation of shared personnel costs, hospital-
wide recurrent costs, and capital costs was conducted based on accepted economic evaluation 
allocation procedures (Shepard et al: 1998; Creese and Parker: 1994). Matsheke notes that 
these criteria are designed as guidelines and that 'the basis of cost allocation may vary subject 
to evaluator's choice and availability of information' (ibid). 
3.2.3 Timeframe for Data Collection 
The timeframe for costing data collection was designed to capture all possible costs associated 
with the Antiretroviral Referral Unit. 'Choosing an appropriate time horizon for the 
evaluation is important, since shifting the time horizon of the evaluation may have. a 
substantial impact on the results of the study' (Drummond et al: 2001, P 71). The timeframe 
for data collection was designed to capture all occasional costs which may not be recorded 
during shorter time periods (Creese and Parker: 1994). 
3.2.4 Real and Nominal Prices 
Nominal pnces are defined as prices in current money terms (www.encyclopedia. 
laborlawtalk.com). Real prices reflect actual purchasing power, and are corrected for the 
effects of inflation (ibid). All monetary values used in this analysis are presented in real 
March 2005 prices. 
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4. Methodology 
This chapter describes the methods employed in this economic evaluation. Section 4.1 
describes the background to the data collection stage. The data identification and collection 
processes for all Antiretroviral Referral Unit epidemiological and economic data are outlined 
in Section 4.2. Section 4.3 summarises data analysis techniques. The determination of costs 
per inpatient day and admission and per outpatient visit is presented in Section 4.4. Finally, 
procedures for the projection of Antiretroviral Referral unit costs are described in Section 4.5. 
4.1 Background to Data Collection 
4.1.1 Case Definition 
All new and existing patients treated by the GF Jooste Antiretroviral Referral Unit during the 
study period were considered eligible for inclusion in this research. All patients treated by the 
Antiretroviral Referral Unit are required by the hospital to be resident in the GF Jooste 
Catchment Area, HIV-positive and above 13 years of age. fu addition to these criteria, all 
such patients are required by the Antiretroviral Referral Unit to be on or preparing for 
HAART treatment and currently attending a designated antiretroviral clinic. 
4.1.2 Data Collection Timeframe 
Data was collected on all patient-specific provider costs associated with the GF Jooste 
Antiretroviral Referral Unit from lSI to 31 51 March 2005 inclusive. fuformation on inpatient 
length of stay in advance and after termination of the study period was collected during April 
2005. All other costing data was collected between March and May 2005. 
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4.1.3 Retrospective Data Sets 
In order to analyse the costs associated with the proposed GF Jooste Antiretroviral Referral 
Unit, this study utilised a combination of current and retrospective expenditure data sets. 
Overhead costs, inpatient personnel costs, and capital costs were based on data from the 2003 
- 2004 Financial Year. All retrospective data sets were harmonised to March 2005 prices 
using STATSSA CPIX inflation data (www.statssa.gov.zalkeyindicators/cpix.asp) to allow 
for differential timing (Drummond et al: 1987). 
4.2 Data Collection 
4.2.1 HAART Coverage and Antiretroviral Referral Unit Utilisation 
Empirical information on the total numbers of patients on or preparing for HAART within the 
GF Jooste Catchment Area was sourced from the Provincial Administration of the Western 
Cape (PA WC: 2005). Historical data on monthly Antiretroviral Referral Unit utilisation 
levels was sourced from Ms. Cordelia Falen, GF Jooste Hospital Administration. 
4.2.2 Descriptive Patient Characteristics 
Information on descriptive patient characteristics was collected on a daily basis throughout 
the study period via patient data capture forms (see Appendix A). Attending clinicians were 
interviewed at the termination of their work shift with the assistance of patient record folders. 
Information on patient age and gender, key diagnoses of patients, HAART status, and all 
other required patient characteristics was captured through this procedure. Separate data 
capture forms were utilised for inpatients and outpatients. 
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4.2.3 Patient-Specific Resource Requirements and Associated Costs 
4.2.3.1 Patient-Specific Resource Requirements 
Data on patient-specific resource consumption was collected on a daily basis throughout the 
study period using the patient data capture forms. For the purposes of this study, patient-
specific resource requirements were recorded and classified according to the following 
categories: 
Laboratory Testing: All laboratory tests performed on patients, including blood tests, 
cerebro-spinal fluid tests, aspirations, and all other tests. 
Imaging and Radiology: All imaging and radiology procedures ordered for patients, 
including X-rays, ultrasounds, and CT Scans. Electrocardiograms were also included in this 
category. 
Medical and Surgical Procedures: All medical and surgical procedures performed on 
patients, including lumbar punctures, gastroscopies, and fine needle aspiration biopsies5• 
Medication: All medication prescribed for patients, including all antiretroviral drugs 
prescribed by the Antiretroviral Referral Unit6 • Discharge medication prescribed for 
inpatients was also recorded and included in this category. 
Intravenous Fluids: All intravenous fluids prescribed for inpatients, including saline fluids, 
dextrose, and rehydration fluids. 
5 Associated laboratory investigations were included under laboratory testing costs. 
6 Antirctroviral drugs dispensed at the primary level were excluded from medication costs. 
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Medical Consumables: All inpatient-specific medical consumable goods, including 
intravenous lines. All other medical and non-medical consumable goods utilised by the 
Antiretroviral Referral Unit were recorded as recurrent costs. 
Counselling Services: All counselling services provided for Antiretroviral Referral Unit 
inpatients, including HAART counselling, pre-test counselling and post-test counselling. 
4.2.3.2 Patient-Specific Costs 
Patient-specific costs were determined through a variety of sources. Laboratory test costs 
were sourced from Mr. Anthony Williams, Senior Laboratory Supervisor, GF Jooste Hospital 
Laboratory and were based on National Health Laboratory Services (NHLS) estimates. 
Pharmaceutical and intravenous fluid costs, including all antiretroviral drugs prescribed by the 
Antiretroviral Referral Unit, were sourced from Mr. Mohammed Sonday, Senior Pharmacist, 
GF Jooste Hospital Pharmacy, and from the Community Health Services Organisation Drug 
Price Listings 2004. The costs of donated drugs, such as fluconazole, were sourced directly 
from drug manufacturers. All drug and pharmaceutical costs were calculated exclusive of 
dispensing costs. 
Imaging, radiology and medical and surgical procedure costs were sourced from the South 
African Uniform Patient Fee Schedule (UPFS) 2005 and from Mr. Shawn Van Schoor, 
Finance Department, GF Jooste Hospital. All imaging and procedures unavailable at GF 
Jooste Hospital and conducted at Groote Schuur Tertiary Hospital on behalf of the 
Antiretroviral Referral Unit were included in these calculations. Medical and non-medical 
consumable costs were sourced from Mr. Robertson and Mr. Mdayi, Supplies Department, 
GF Jooste Hospital. Counselling costs were provided by the Lifeline Counselling Service, 
Cape Town. All costs were measured in 2005 South African Rands. 
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4.2.4 Capital Resource Requiremeuts and Associated Costs 
4.2.4.1 Antiretroviral Referral Unit Building 
Antiretroviral Referral Unit building resource requirements were provided by Dr. Graeme 
Meintjes, Medical Consultant, GF Jooste fufectious Disease Clinic (Meintjes: 2004a). A full 
list of these requirements is provided in Appendix B. The corresponding costs associated 
with these requirements were collected from Mr. Hein Hanakom, Senekal Allen Quantity 
Surveyors, Cape Town. 
4.2.4.2 Antiretroviral Referral Unit Equipment 
Medical and non-medical equipment requirements were sourced from Dr. Graeme Meintjes. 
This included all medical and non-medical equipment required for the full operation of an 
Antiretroviral Referral Unit. A full list of equipment requirements is provided in Appendix B. 
Associated equipment costs were sourced from Ms. Lezel Adams, fuventory Department, GF 
Jooste Hospital, and directly from medical equipment manufacturers. fustallation and 
maintenance fees were included for all Antiretroviral Referral Unit equipment. 
4.2.4.3 Antiretroviral Referral Unit Staff Training 
Training in the management of patients on antiretroviral drugs is periodically provided to 
Antiretroviral Referral Unit clinical staff. Training programme information and associated 
costs were sourced from the Medicines fuformation Centre, University of Cape Town. 
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4.2.4.4. Medical Ward Capital 
Antiretroviral Referral Unit inpatients are treated in the GF Jooste Hospital Medical Ward. 
Capital resources required for Antiretroviral Referral Unit inpatient care, and associated costs 
per inpatient day, were based on prior costing data for HIV -positive inpatients at GF Jooste 
Hospital (Cleary et al: 2005). 
4.2.5 Recurrent Resource Requirements and Associated Costs 
4.2.5.1 Antiretroviral Referral Unit Personnel 
Medical and non-medical personnel resource requirements were sourced from attending 
clinicians at the Antiretroviral Referral Unit. A clinician data capture form was used to 
inform estimates of the level and distribution of clinical staff time required for full 
Antiretroviral Referral Unit operation (see Appendix A). Associated costs were provided by 
Mr. George Julius, Finance Department, GF Jooste Hospital. Personnel costs include all 
benefits, scarce skills bonuses, committed overtime, pension funds and medical aid 
contributions. 
4.2.5.2 Medical Ward Oinical Personnel 
In addition to Antiretroviral Referral Unit clinical personnel, Antiretroviral Referral Unit 
inpatients receive treatment from GF Jooste Medical Ward clinical staff. Clinical personnel 
resource requirements for Antiretroviral Referral Unit inpatient care, and associated costs per 
inpatient day, were based on prior data for HIV -positive inpatients at GF Jooste Hospitaf 
(Cleary et al: 2005). 
1 Antiretroviral Referral Unit clinical staff costs were deducted from medical ward clinical personnel costs where 
double counting occurred. 
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4.2.5.3 Overhead Costs 
Monthly medical and surgical supplies requirements were sourced from attending clinicians at 
the Antiretroviral Referral Unit. A full list of these resource requirements is provided in 
Appendix B. Associated costs were sourced from Mr. Mdayi, Supplies Department, GF 
Jooste Hospital. Antiretroviral Referral Unit administrative requirements were sourced from 
Dr. Graeme Meintjes, while associated costs were provided by Mr. George Julius. All other 
general overhead costs for the Antiretroviral Referral Unit and the GF Jooste Medical Ward, 
as well as associated costs per outpatient visit and per inpatient day, were based on prior 
overhead cost data for HIV -positive inpatients and outpatients at GF Jooste Hospital (Cleary 
et al: 2005) and include utility, administrative8, cleaning and security personnel costs. 
4.3 Data Analysis 
The data for this study was entered into the Microsoft EXCEL Version 9.0 software package 
(Seattle, Washington: 2000). Data sorting, data cleaning, data analysis and the generation of 
associated graphs, tables and charts were performed using EXCEL. Extrapolation of 
prospective HAART coverage and Associated Antiretroviral Referral Unit demand levels was 
also performed using EXCEL. Manual calculations using a hand calculator were performed 
where necessary. 
8 Antiretroviral Referral Unit administrative costs are supplementary to the administrative costs recorded under 
general overhead costs. 
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4.4 Cost per Outpatient Visit, per Inpatient Day and per Inpatient Admission 
Cost per outpatient visit includes total patient-specific costs as well as Antiretroviral Referral 
Unit capital and recurrent costs. Cost per inpatient day and cost per inpatient admission 
includes total patient-specific costs as well as Antiretroviral Referral Unit and Medical Ward 
capital and recurrent costs. Allocation procedures for determining the distribution of shared 
capital and recurrent costs across inpatients and outpatients were developed in accordance 
with accepted economic evaluation criteria (Shepard et aT: 1998), or based on prospective 
utilisation estimates from Dr. Graeme Meintjes. The following formulae were utilised in 
these calculations: 
Formula 4.1: Cost per Outpatient Visit 
Cost per Outpatient Visit Antiretroviral Referral Unit Capital Costs per Outpatient Visit + 
Antiretroviral Referral Unit Recurrent Costs per Outpatient Visit + 
Outpatient-Specific Costs per Outpatient Visit 
Formula 4.2: Cost per Inpatient Day 
Cost per Inpatient Day Antiretroviral Referral Unit Capital Costs per Inpatient Day + 
Antiretroviral Referral Unit Recurrent Costs per Inpatient Day + 
Inpatient-Specific Costs per Inpatient Day + 
Medical Ward Capital Costs per Inpatient Day + 
Medical Ward Personnel Costs per Inpatient Day 
Formula 4.3: Cost per Inpatient Admission 
Cost per Inpatient Admission = Total Cost per Inpatient Day x 
Average Length of Stay 
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4.4.1 Patient-Specific Costs 
4.4.1.1 Outpatient-Specific Costs 
A micro costing procedure was employed for all patient-specific costing categories. The total 
cost of each patient-specific costing category was calculated for each outpatient visit, based 
on study period data. Total outpatient-specific costs per outpatient visit were then calculated. 
Total outpatient-specific costs were then divided by total outpatient visits to determine the 
average outpatient-specific cost per outpatient visit. 
4.4.1.2 Inpatient-Specific Costs 
A micro costing procedure was employed for all inpatient-specific costs. The total cost of 
each patient-specific costing category was calculated for each inpatient admission, based on 
study period data. Total inpatient-specific costs were then divided by total inpatient days to 
determine the average inpatient-specific cost per inpatient day. 
4.4.2 Capital Costs 
4.4.2.1 Antiretroviral Referral Unit Capital Costs 
A step-down costing procedure was employed for all Antiretroviral Referral Unit capital 
costs. Equivalent annual costs for 2005 were calculated for all capital items based on their 
replacement costs9• Capital costs were annuitised assuming an average life span of 30 years 
for buildings, 10 years for equipment and 2 years for staff training (Shepard et al: 1998) to 
produce annual capital costs. A discount rate of 8.0% per annum was employed to allow for 
depreciation and the opportunity cost of capital investment. This discount rate is equivalent 
9 For CT Scanner equipment costs, prospective Antiretroviral Referral Unit utilisation was estimated at 5.0% of 
total hospital utilisation, based on consultation with Dr. Graeme Meintjes. Utilisation-based CT Scanner costs 
were then annuitised as for other Antiretroviral Referral Unit equipment. 
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to the return on long tenn government bonds in South Africa, In accordance with 
methodological recommendations (Drummond et al: 2001). 
Annuitised Antiretroviral Referral Unit building and equipment costs were allocated to 
inpatients and outpatients according to relative utilisation estimates sourced from Dr. Graeme 
Meintjes. Staff training costs were allocated according to staff time distribution data for the 
study period. Total monthly inpatient and outpatient Antiretroviral Referral Unit capital costs 
were then divided by total monthly outpatient visits and total monthly inpatient days 
respectively to produce capital costs per outpatient visit and per inpatient day. 
4.4.3 Recurrent Costs 
4.4.3.1 Antiretroviral Referral Unit Clinical Personnel Costs 
Total monthly clinical personnel costs were calculated by combining data on clinical staff 
time distribution with associated monthly salary information. Clinical personnel costs were 
allocated to inpatients and outpatients according to data on inpatient and outpatient contact 
time sourced from the clinician data capture fonns (see Appendix D). Inpatient and outpatient 
clinical personnel costs for the Antiretroviral Referral Unit were then divided by total 
inpatient days and total outpatient visits respectively to produce the clinical personnel cost per 
outpatient visit and per inpatient day. 
4.4.3.2 Antiretroviral Referral Unit Overhead Costs 
Antiretroviral Referral Unit administration and medical and surgical supplies costs were 
allocated to outpatients and inpatients according to relative facility utilisation estimates 
sourced from Dr. Graeme Meintjes. These costs were then divided by total outpatient visits 
and total inpatient days respectively to produce the respective cost per outpatient visit and per 
inpatient day. 
33 
4.5 Cost-Outcome Description 
The cost per successful outcome for Antiretroviral Referral Unit treatment was calculated for 
inpatients and outpatients. Information from the patient data capture forms on response to 
treatment was used to develop the outcome measure. Attending clinicians were asked to 
categorise inpatients and outpatients as 'improved', 'stabilised', 'no change', 'deteriorated', 
or 'died' 10. Patients assessed as 'improved' or 'stabilised' were considered to have been 
successfully treated. The cost per successful outpatient visit, the cost per successful inpatient 
day and the cost per successful inpatient admission were then calculated. 
4.6 Modelling of Prospective Costs 
The modelling of prospective costs per outpatient visit, per inpatient day and per inpatient 
admission is designed to assist in determining the resource requirements associated with 
projected demand for secondary hospital services by patients on or preparing for HAART in 
the GF Jooste Catchment Area. A five-year projection period from 2006 to 2010 was utilised 
for the modelling of prospective year-on-year costs. 
4.6.1 Prospective HAART Coverage 
Projected HAART coverage levels, include all patients on or preparing for antiretroviral 
treatment in the GF Jooste Catchment Area, were calculated based on the linear extrapolation 
of coverage levels for December 2004 to March 2005. The following formula was used: 
IO Standardised outcome measures, such as viral suppression levels, were considered to be more appropriate to 
the measurement of the direct effects of antiretroviral therapy, rather than to measurement of the specialised 
services provided by the Antiretroviral Referral Unit. In many cases, the treatment provided by the 
Antiretroviral Referral Unit may not affect viral suppression or CD4 levels, while still resulting in an 
improvement or stabilisation of the patient's health condition. 
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Fonnula 4.4: Projected Monthly HAART Coverage 
Coverage Month A 
Coverage Month (A-n) 
Coverage Month A 
Coverage in Projection Month 
Coverage in Prior Month 
{ [ ( Coverage Month (A-I) - Coverage Month (A-2) ) + 
( Coverage Month (A-2) - Coverage Month (A-3) ) + 
( Coverage Month (A-3) Coverage Month (A-4) ) ] I 
( 3 ) } + Coverage Month (A-I) 
4.6.2 Prospective Antiretroviral Referral Unit Demand 
Based on prior Antiretroviral Referral Unit utilisation data (see Appendix C), the proportion 
of persons on or preparing for HAART requiring Antiretroviral Referral Unit services was 
calculated for the projection period. The proportions of prospective patients requiring 
inpatient and outpatient care were then calculated based on Antiretroviral Referral Unit 
admission data for the study period (see Appendix C). Average monthly outpatient visit 
frequency and average monthly inpatient length of stay for the study period were then used to 
calculate prospective monthly outpatient visits and inpatient days. 
4.6.3 Prospective Antiretroviral Referral Unit Costs 
Prospective costs per outpatient visit, per inpatient day and per inpatient admission were 
estimated based on projected demand for Antiretroviral Referral Unit services in the GF 
Jooste Catchment Area. All patient-specific, capital and recurrent costs were recategorised as 
fixed and variable costs for inpatients and outpatients. The model assumes that initial 
Antiretroviral Referral Unit and GF Jooste Medical Ward fixed resources maintain excess 
capacityll, and will not be expanded during the projection period. Based on consultation with 
Dr. Graeme Meintjes, specialist clinical personnel resources were considered to remain 
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independent of projected demand levels, and were categorised as fixed costs throughout the 
projection period. Total year-on-year fixed costs per outpatient visit, per inpatient day and 
per inpatient admission were then calculated based on prospective demand levels. 
All variable costs per outpatient visit, per inpatient day and per inpatient admission were 
assumed to remain independent of total Antiretroviral Referral Unit utilisation levels, and 
were held constant throughout the projection periodl2 • Total fixed costs per outpatient visit, 
per inpatient day and per inpatient admission were then combined with their respective 
variable costs to produce total projected costs per outpatient visit, per inpatient day and per 
inpatient admission. 
II Excess capacity is defined as the amount by which actual output falls short of potential output at operational 
capacity (Lipsey et al: 1992), and is assumed in this case due to low levels of demand at baseline. 
12 In economic evaluation terminology, these costs are described as constant marginal variable costs (Drummond 
et al: 1988). 
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5. Epidemiological Results 
5.1 Demand for Antiretroviral Referral Unit Services 
'-
Total numbers of patients on or preparing for HAART and attending an antiretroviral clinic 
within the GF Jooste Catchment Area between October 2004 and March 2005 are presented in 
Table 5.1 and Figure 5.1 13. HAART patients include all patients on or preparing for 
HAART14. 
Table 5.1: HAART Patients Attending Antiretroviral Clinics in the GF Jooste Catchment Area 
October November December January February 
2004 2004 2004 2005 2005 
OF Jooste 
197 218 235 248 258 
SiteB 
(Khayelitsha) 
593 606 597 629 678 
SiteC 
403 422 415 431 450 (Nolungile) 
Mitchells Plain 
238 285 306 341 378 
13 
Ouguletu 
403 422 443 473 532 
Crossroads 
19 36 50 62 62 
Total 
1,853 1,989 2,046 2,184 2,358 
!O 
Figure 5.1: HAART Patients Attending AntiretroviraJ Clinics in the GF 
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14 Patients preparing for HAART were included by adding the total number of new starts in the succeeding 
month to each preceding month. 
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Total numbers of patients on or preparing for HAART and attending the Antiretroviral 
Referral Unit between October 2004 and March 2005 are presented in Table 5.2 and Figure 
5.215. Total patients include all Antiretroviral Referral Unit inpatients and outpatients. 
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Figure 5.2: Antiretroviral Referral Unit Treatment Levels, 











Total monthly Antiretroviral Referral Unit treatment levels, as a proportion of patients on or 
preparing for HAART and attending antiretroviral clinics within the OF Jooste Catchment 
Area, are presented in Figure 5.3. From October 2004 to March 2005, an average monthly 
level of 3.33% of HAART patients required treatment from the Antiretroviral Referral Unitl6• 
Figure 5.3: HAARt Patients Requiring Antiretroviral Rererral Unit 
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5.2 Study Sample Size 
All patients attending the Antiretroviral Referral Unit during the study period met inclusion 
criteria. During the time period 1 st to 31 SI March 2005 inclusive, information on 48 
outpatients and 25 inpatients was collected from the Antiretroviral Referral Unit. A total of 
62 outpatient visits were made to the Antiretroviral Referral Unit by the 48 outpatients during 
this time period. 
15 Source: GF Jooste Hospital Administration. 
16 See Appendix C fOT the derivation of the average monthly level ofHAART patients. 
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5.3 Descriptive Patient Characteristics 
5.3.1 Patient Gender 
Gender information was recorded for all 48 outpatients and all 25 inpatients in the study 
sample. The gender of patients was predominantly female for both outpatients (77.0%) and 
inpatients (76.0%). The distributions of Antiretroviral Referral Unit outpatients and 
inpatients by gender are illustrated in Figure 5.4. 










I 5.3.2 Patient Age 
Data on patient age was recorded for 47 outpatients and 24 inpatients. Inpatient age is 
represented as age at date of admission. The mean age at date of visit was 35.96 years for 
I outpatients and the mean age at date of admission was 34.0 years for inpatients. The distributions of Antiretroviral Referral Unit inpatients and outpatients across age categories 
are presented in Figure 5.5. 
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5.3.3 Attending Antiretroviral Clinic 
Infonnation on attending antiretroviral clinic was collected for 45 outpatients and 22 
inpatients. For outpatients, the majority of patients attended the Site B Clinic (26.67%), the 
GF Jooste Infectious Disease Clinic (20.0%) and the Guguletu Clinic (20.0%). For inpatients, 
the majority of patients attended the Site B Clinic (27.27%) followed by the GF Jooste 
Infectious Disease Clinic (22.73%) and the Site C Clinic (18.18%). The distributions of 
outpatients and inpatients by attending antiretroviral clinic are illustrated in Figure 5.6. 
Figure 5.6: Patient Antiretroviral Clinic Distributions 
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5.3.4 WHO mv / AIDS Clinical Stage 
The WHO HIV / AIDS Clinical Stage was recorded for all 48 outpatients and all 25 
inpatients. Patient clinical stage was assessed based on the patient's medical record and 
clinician assessment. For outpatients, a total of21 patients (43.75%) were assessed as clinical 
stage 4 and a further 23 patients (47.92%) as clinical stage 3. The median clinical stage for 
outpatients was stage 3. For inpatients, 22 of25 patients (88.0%) were at clinical stage 4 with 
the remaining three patients (12.0%) at clinical stage 3. The median clinical stage for 
inpatients was stage 4. The distributions of outpatients and inpatients by clinical stage are 
presented in Figure 5.7. 
Figure 5.7: Patient WHO HIY / AIDS Clinical Stage Distributions 
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5.3.5 CD4 Count 
Most recent CD4 count data was recorded for 44 outpatients and 19 inpatients. For 
outpatients, 20.45% presented with a CD4 count below 50 ~ml, and a further 27.27% with a 
CD4 count between 51 and 200 ~m1. The mean outpatient CD4 count was 175.07 ~m1. For 
inpatients, 68.42% presented with a CD4 level below 50 ~ml, and a further 26.32% with a 
CD4 count between 51 and 200 ~m1. The mean inpatient CD4 count was 77.58 ~m1. The 
distributions of outpatients and inpatients by CD4 count are illustrated in Figure 5.8. 
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5.4 Antiretroviral Data 
5.4.1 HAART Status 
HAART status was recorded for all 48 outpatients and all 25 inpatients. 68.75% of 
outpatients were receIvmg HAART while a further 29.17% were prepanng for HAART 
initiation at date of visit. One outpatient was suspended from HAART treatment at date of 
visit. 64.0% of inpatients were receiving HAART, while 28.0% were at the preparatory stage 
at date of admission. Two inpatients were suspended from HAART treatment at date of 
admission. The distributions of outpatients and inpatients by HAART status are illustrated in 
Figure 5.9. 
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5.4.2 Time Since HAART Initiation 
The date of HAART initiation was recorded for 31 of 34 outpatients on HAART and 17 of 18 
inpatients on HAART. Time since HAART initiation was calculated based on date of visit 
for outpatients and date of admission for inpatients. For outpatients, the mean time since 
initiation was 10.06 months and the median time 8 months. For inpatients, corresponding 
mean time was 5.47 months and median time 2 months. The distributions of outpatients and 
inpatients by time elapsed since HAART initiation are presented in Figure 5.10. 
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5.4.3 HAART Regimen 
Information on HAART regimen was recorded for 32 of 34 outpatients on HAART and 17 of 
18 inpatients on HAART. 62.5% of HAART outpatients received a combination of 3TC, 
D4T and Efavirenz antiretrovirals. Similarly, 66.67% of HAART inpatients received this 
combination. The distributions of outpatients and inpatients on HAART by HAART regimen 
are illustrated in Figure 5.11. 
Figure 5.11: Patient HAART Regimen Distributions 17 
n = 32 


















The Kaletra Regimen is composed of Kaletra and a combination of two other antiretroviral drugs, including 
DDI, D4T or AZT. 
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5.4.4 Antiretroviral Drug Type 
Based on HAART regimen data, information on the types of individual antiretroviral drugs 
used by HAART outpatients and inpatients was derived. Of the 32 outpatients with HAART 
regimen information, 96.88% received 3TC and 78.13% received D4T. Of the 18 inpatients 
with HAART regimen information, 94.44% received 3TC and 94.44% received D4T. The 
levels of individual antiretroviral drug types across inpatients and outpatients on HAART are 
illustrated in Figure 5.12. 
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5.5 Length of Stay and Visit Duration 
5.5.1 Inpatient Length of Stay 
Infonnation on total length of stay at GF Jooste Hospital was available for all 25 inpatients. 
28.0% of inpatients were hospitalised for 7 days or less, while 36.0% were hospitalised for 8 
to 14 days. 20.0% (5 patients) were admitted for 14 to 21 days, and a further 16.0% (4 
patients) for longer than 3 weeks. The mean length of stay was 14.60 daysls. The distribution 
of inpatients according to length of stay is presented in Figure 5.13. 
Figure 5.13: Inpatient Length of Stay 
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5.5.2 Outpatient Duration of Visit 
n = 25 
Infonnation on duration of outpatient visit was available for 38 out of 62 outpatient visits. 
The average length of outpatient visit was 47.37 minutes. The distribution of outpatient visits 
according to duration of visit is presented in Figure 5.14. 
Figure 5.14: Outpatient Duration of Visit 
5% 
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0 > 60 minutes 
n = 38 
18 This figure includes all inpatient days accrued in advance and after termination of the study period (365 
inpatient days). Average inpatient length of stay for the study period was 9.60 days (240 days). 
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5.6 Patient Diagnoses 
5.6.1 Outpatient Diagnoses 
Diagnosis information was collected for all 62 outpatient visits. Individual outpatients 
frequently presented with multiple diagnoses, and a total of 75 outpatient diagnoses were 
recorded. Outpatient primary and secondary diagnostic groups and associated frequencies are 
presented in Table 5.3. Of 48 outpatients, 33 .33% were diagnosed with Tuberculosis. 
Primary diagnostic groups are presented in Figure 5.15. 49 .33% of all outpatient diagnoses 
were categorised as 'Infections' and 24.0% as 'Antiretroviral Drug Related' . 
Table 5.3: Outpatient Primary and Secondary Diagnostic Groups 
Primary Diagnostic Group Secondary Diagnostic Group 
Stavudine (D4T) Related Neuropathy 
Drug Induced Hepatitis 
Drug Induced Skin Rash 
Antiretroviral Drug Related Lactic Acidosis 
Lipodystrophy 
Hyperlactataemia 
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Figure 5.15: Outpatient Primary Diagnostic Groups 
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5.6.2 Inpatient Diagnoses 
Diagnosis information was collected for all 25 inpatient admissions. Individual inpatients 
frequently presented with multiple diagnoses, and a total of 36 inpatient diagnoses were 
recorded. Inpatient primary and secondary diagnostic groups and associated frequencies are 
presented in Table 5.4. Of25 inpatients, 40.0% were diagnosed with Tuberculosis and 24.0% 
with Cryptococcal Meningitis. Primary diagnostic groups are presented in Figure 5.14. 
55.56% of inpatient diagnoses were classified as 'Infections' and a further 16.67% as 
'Malignancies' . 
Table 5.4: Inpatient Primary and Secondary Diagnostic Groups 
Primary Diagnostic Group Secondary Diagnostic Group 
Antiretroviral Drug Related 
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Figure 5.16: Inpatient Primary Diagnostic Groups 
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5.7 Patient Outcomes 
5.7.1 Response to Treatment 
Patient response to treatment was assessed by the attending clinician for 51 of 62 outpatient 
visits and 20 of 25 inpatient admissions. For outpatient visits, 45.1 % of patients improved 
with treatment and a further 27.45% were stabilised. 25.49% of visits were recorded as 
producing no change in health status. For inpatient admissions, 40.0% were recorded as 
improving with treatment while 25.0% recorded stabilisation. 15.0% of inpatient admissions 
were recorded as showing no change in health status. Four deaths (20.0% of known inpatient 
outcomes) occurred amongst inpatients. The distributions of outpatient visits and inpatient 
admissions by response to treatment outcome category are presented in Figure 5.17. 
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5.7.2 Destination of Patient 
Post-treatment patient destination was recorded for 61 of 62 outpatient visits and 23 of 25 
inpatient admissions. For outpatient visits, 88.53% returned to primary care of which 61.11 % 
were scheduled for return appointments at the Antiretroviral Referral Unit. A further 3.28% 
were admitted to inpatient care and 6.56% to tertiary care. For inpatients, 30.43% were 
returned to primary care, of which figure 57.15% were scheduled to return for outpatient 
Antiretrovira1 Referral Unit treatment. 52.17% of inpatients were transferred to other 
secondary hospital care, including St. Luke's Hospice, Lentegeur Hospital 19, and Tuberculosis 
hospitals. The distributions of patient destinations for inpatients and outpatients are shown in 
Figure 5.18. 
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19 The Lentegeur Hospital Carnation Ward is a secondary level step-down care facility. The Carnation Ward is 
administered as part of GF Jooste Hospital. 
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6. Patient-Specific Costing Results 
6.1 Laboratory Testing Costs 
Laboratory testing costs may be divided by laboratory test type. 73.0% of outpatient 
laboratory testing costs were generated by blood tests. Similarly, 74.98% of inpatient 
laboratory testing costs were generated by blood tests. The distributions of laboratory testing 
costs by laboratory test type for inpatients and outpatients are presented in Figure 6.1. 




















6.2 Imaging and Radiology Costs 
Imaging and radiology costs may be divided by type of imaging or radiology test. 49.27% of 
outpatient imaging and radiology costs were generated by CT scans, while a further 38.02% 
were accrued by X-Rays. 57.88% of inpatient imaging and radiology costs were generated by 
CT scans and a further 27 .19% by X-Rays. The distributions of imaging and radiology costs 
by test type for inpatients and outpatients are presented in Figure 6.2 . 














6.3 Medication Costs 
Medication costs may be divided according to a number of broad medication categories. 
44.33% of outpatient medication costs were accrued by non-antiretroviral antimicrobial 
medication, while a further 37.01 % were caused by antiretroviral drugs. 67.8% of inpatient 
medication costs were assigned to non-antiretroviral antimicrobials. The distributions of 
medication costs for inpatients and outpatients by medication type are presented in Figure 6.3. 



















Includes vitamin, nutritional and electrolyte replacement supplements. 
Includes all discharge medication. 
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6.4 Medical and Surgical Procedures Costs 
Medical and surgical procedures costs may be classified according to procedure type . 32.42% 
of outpatient procedures costs were caused by fine needle aspiration biopsies, and 30.31 % by 
upper gastro-intestinal endoscopies. For inpatients, 42.65% of procedure costs were caused 
by lumbar punctures, and a further 30.05% by upper gastro-intestinal endoscopies. The 
distributions of medical and surgical procedure costs by procedure type for inpatients and 
outpatients are presented in Figure 6.4. 
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6.5 Intravenous Fluids Costs 
Inpatient intravenous fluid costs may be divided by fluid type. 62.03% of intravenous fluid 
costs were accrued by saline fluids. The distribution of intravenous fluid costs by fluid type is 
presented in Figure 6.5. 
Figure 6.5: Intravenous Fluid Cost Distribution 
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Inpatient counselling costs can be divided according to counselling type. 40.0% of 
counselling costs were caused by Social Worker Counselling. The distribution of counselling 
costs by counselling type is illustrated in Figure 6.6. 
Figure 6.6: Counselling Cost Distribution 
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7. Costing and Cost-Outcome Results 
7.1 Cost per Outpatient Visit 
7.1.1 Outpatient-Specific Costs 
Outpatient-specific costs per outpatient visit to the Antiretroviral Referral Unit are presented 
in Table 7.1. Total monthly costs, cost allocation procedures and associated allocation factors 
are also presented. The distribution of outpatient-specific costs by costing category is 
presented in Figure 7.1. 
Table 7.1: Outpatient-Specific Costs per Outpatient Visit 
Total 
Allocation Allocation 
Monthly Total Cost per 
Category Monthly 
Procedure Factor 
Outpatient Outpatient Outpatient 
Cost Cost Visits Visit 
Laboratory Testing 
8,646.00 Direct 1.00 8,646.00 62 139.45 
Imaging + 
6,423.92 Direct 1.00 6,423.92 62 103.61 
Radiology 
Medication 
2,553.70 Direct 1.00 2,553.70 62 41.19 
Medical + Surgical 
6,704.76 Direct 1.00 6,704.76 62 108.14 
Procedures 
Total 
24,328.38 24,328.38 392.39 
Figure 7.1: Distribution of Outpatient-Specific Costs 
o Laboratoy Testing 
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o Medical and Surgical Procedures 
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7.1.2 Recurrent Costs 
7.1.2.1 Clinical Personnel Costs 
Clinical personnel costs per outpatient visit are presented in Table 7.2. Total monthly costs, 
cost allocation procedures and associated allocation factors20 are also presented. The 
distribution of clinical personnel costs by clinical personnel category is presented in Figure 
7.2. 









7,798.05 % Working Hours 0.40 3,119.22 
Consultant (2) 
13,467.32 % Working Hours 0.46 6,194.97 
Medical Officer 
(I) 21,633.64 % Working Hours 0.19 4,110.39 
Medical Officer 
(2) 20,568.20 % Working Hours 0.70 14,397.74 
Nursing Sister 
6,002.19 Direct· 1.00 6,002.19 
Total 
69,469.40 33,824.51 
* Tbe Antlretrovlral Referral VOlt Nursmg Sister provides outpatient care only. 
Figure 7.2: Distribution of Clinical Personnel Costs (Outpatients) 
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20 The derivation of monthly clinical personnel costs and associated allocation factors is presented in Appendix D. 
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7.1.2.2 Overhead Costs 
Overhead costs per outpatient visit are presented in Table 7.3. Cost allocation procedures and 
associated allocation factors are also presented. The distribution of overhead costs by 
overhead cost category is presented in Figure 7.3 . 
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7.1.3 Capital Costs 
Capital costs per outpatient visit are presented in Table 7.4. Cost allocation procedures and 
associated allocation factors are also presented. The distribution of capital costs by costing 
category is presented in Figure 7.4. 
Table 7.4: Capital Costs per Outpatient Visit 
Replacement Annual Allocation Allocation 
Monthly 
Category 




2,845,995.75 252,802.12 % Utilisation 0.90 18,960.16 
Referral Unit 
Medical 
765,598.78 114,096.48 % Utilisation 0.90 40,412.20 
Equipment 
Administrative 








3,661,894.97 376,618.17 28,165.74 
.. * Based on average allocatIon factors of surveyed chmcal personnel (see Table 7.2). 
Figure 7.4: Distribution of Capital Costs (Outpatients) 
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7.1.4 Total Cost per Outpatient Visit 
Total costs per outpatient visit are presented in Table 7.5. The distribution of total costs per 
outpatient visit is presented in Figure 7.5. 
Table 7.5: Cost per Outpatient Visit 
Category 
Cost per Outpatient 





545.56 33 .84 
Clinical Personnel 
Recurrent: 
220.10 13 .65 
Overheads 
Capital 454.29 28.18 
Total 
1,612.34 100.00 
Figure 7.5: Distribution of Costs per Outpatient Visit 
63 
III Outpatient-Specific 
• Clinical Personnel 
o Overheads 
o Capital 
Cost-Outcome per Outpatient 
The cost-outcome description Referral treatment successful 
outpatient visit is presented in Patients assessed as or by 








21 See Section 5.6.1 for a full of patient outcome measurement and results. 
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7.2 Cost per Inpatient Day 
7.2.1 Inpatient-Specific Costs 
Inpatient-specific costs per inpatient day are presented in Table 7.7 . Cost allocation 
procedures and associated allocation factors are also presented. The distribution of inpatient-
specific costs by costing category is presented in Figure 7.6. 









9,635.65 Direct 1.00 9,635 .65 
Imaging + 
5,468.12 Direct 1.00 5,468. 12 
Radiology 
Medication* 
4,841.47 Direct 1.00 4,841.47 
Medical + Surgical 
6,762.58 Direct 1.00 6,762.58 
Procedures 
Intravenous Fluids 
1,0 16.91 Direct 1.00 1,0\6.91 
Consumables 
16,921.24 Direct 1.00 16,921.24 
Counselling 
109.10 Direct 1.00 109. 10 
Total 
44,755.07 44,755.07 
* Includmg all discharge medication . 
Figure 7.6: Distribution of Inpatient-Specific Costs 
12% 
15% 
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186.48 
7.2.2 Recurrent Costs 
7.2.2.1 Clinical Personnel Costs 
Clinical persOlmel costs per inpatient day are presented in Table 7.8. Total monthly costs, 
cost allocation procedures and associated allocation factors are also presented22 • The 
distribution of clinical personnel costs by personnel category is presented in Figure 7.7 . 
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22 The derivation of monthly clinical personnel costs and associated allocation factors is presented in Appendix D. 
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7.2.2.2 Costs 
l\fprh"<lrt costs per inpatient are "''''-lU''',U in Table 7.9. procedures and 
associated allocation factors are also ",,. •• ,,,,.,t,,,,ri 
Total 
Allocation Allocation 














7.2.3 Capital Costs 
Capital costs per inpatient day are presented in Table 7.10. Cost allocation procedures and 
associated allocation factors are also presented. A sub-total for Antiretroviral Referral Unit 
capital costs per inpatient day is provided. The distribution of capital costs for inpatient care 
is presented in Figure 7.8. 
Table 7.10: Capital Costs per Inpatient Day 
Replacement Annual Allocation Allocation 
Monthly Total Cost per 
Category Inpatient Inpatient Inpatient 
Value Cost Procedure Factor 
Cost Days Day 
Antiretroviral 
2,845,995.75 252,802.12 % Utilisation 0.10 2,106.68 240 8.78 
Referral Unit 
Medical 










0.53 133.74 240 0.56 
Hours· 
Sub-Total 
3,661,894.97 376,618.17 3,219.11 13.41 
Medical Ward 
8,054,712.86 715,478.40 Direct 1.00 59,623.20 240 248.43 
Capital Costs 
Total 
11,716,607.82 1,092,096.57 62,842.31 261.84 
* Based on average allocation factors of surveyed clinical personnel (see Table 7.8). 
Figure 7.8: Distributi.on ofCapitai Costs (Inpatients) 
C Administrative Equipment 
• Antiretroviral Referral Unit Building 
o Medical Equipment 
o Staff Training 
• Medical Ward Capital 
95% 
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7.2.4 Total Cost per Inpatient Day and per Inpatient Admission 
Total costs per inpatient day and per inpatient admission are presented in Table 7.11. The 
distribution of total costs per inpatient day and per inpatient admission is presented in Figure 
7.9. 
Table 7.11: Cost per Inpatient Day and per Inpatient Admission 
Category 
Cost per Inpatient Average Length of Cost per Inpatient 
Day Stay Admission 
Inpatient-Specific 
186.48 14.60 2,722.61 
Recurrent: 
304.27 14.60 4,442.34 
Clinical Personnel 
Recurrent: 
411.02 14.60 6,000.89 
Overheads 
Capital 
261.84 14.60 3,822.86 
Total 
1,163.61 16,988.71 
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7.2.5 Cost-Outcome per Inpatieut Day and per Inpatient Admission 
The cost-outcome of Antiretroviral Referral Unit treatment per successful inpatient day and 
per successful inpatient admission are presented in Table 7.12 and Table 7.13. Patients 
assessed as 'improved' or 'stabilised' by the attending clinician were classified as 
successfully treated23• 
Table 7.12: Cost-Outcome per Inpatient Day 
Category Monthly Cost 
Successful Inpatient Cost per Successful 
Days Inpatient Day 
Inpatient-Specific 
44,755.07 125 358.04 
Recurrent: 
73,024.89 125 584.20 
Clinical Personnel 
Recurrent: 
98,644.06 125 789.15 
Overheads 
Capital 
62,842.31 125 502.74 
Total 
279,266.33 2,234.13 
Table 7.13: Cost-Outcome per Inpatient Admission 
Category I MonthI C~ Successfu.l I?patient Cost per Successful y AdmIssIons Inpatient Admission 
Inpatient-Specific 44,755.07 . 13 3,442.70 
Recurrent: 






Capital 62,842.31 13 4,834.02 
Total 
279,266.33 21,482.03 
23 See Section 5.6.1 for a full description of patient outcome measurement and results. 
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8. Costing Projection Results 
8.1 Projected HAART Coverage 
Projected year-on-year monthly antiretroviral coverage levels for the GF Jooste Catchment 
Area are presented by antiretroviral clinic in Table 8.1 and in Figure 8.1. Coverage levels 
include all patients on or preparing for antiretroviral treatment. 





















Marth 2005 Marth 2006 Marth 2007 Marth 2008 Marth 2009 Marth 2010 
287 454 622 790 958 1,126 
756 1,240 1,722 2,204 2,686 3,168 
492 750 1,010 1,270 1,530 1,790 
485 1,107 1,733 2,359 2,985 3,611 
667 1 2,261 3,059 3,857 4,655 
144 532 922 1,312 1,702 2,092 
2,831 5,547 8,271 10,995 13,719 16,443 
Figure 8.1: Projeeted Year-on-Year Monthly Antiretroviral Coverage by 
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8.2 Projected Antiretroviral Referral Unit Demand 
Projected year-on-year monthly Antiretroviral Referral Unit demand levels for the GF Jooste 
Catchment Area are presented in Table 8.2 and Figure 8.2. Based on prior Antiretroviral 
Referral Unit utilisation levels (see Appendix C), a constant level of 3.33% of persons on or 
preparing for HAART requiring Antiretroviral Referral Unit care was assumed for the 
projection period24. 
A constant ratio of 66:34 was employed to determine the distribution of patients requiring 
outpatient and inpatient care (see Appendix C), while each outpatient was assumed to require 
1.29 visits per month based on study period data25. Each patient requiring inpatient care was 
assumed to require a length of stay of 14.60 days26. Total outpatient visits and total inpatient 
days were then calculated for the projection period. 
24 This excludes the March 2005 level of 2.5 8%, which was based on study period utilisation data. 
25 A total of 62 visits were made by 48 different outpatients during the study period. This produces an average 
outpatient visit frequency of 1.29 visits per month. 
26 See Section 5.4.1 for a full discussion of inpatient length of stay measurement and results. 
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Table 8.2: Projected Antiretroviral Referral Unit Demand, 2005 - 2010 
March 2005 March 2006 March 2007 March 2008 March 2009 March 2010 
HAART 
2,831 5,547 8,271 10,995 13,719 16,443 
Patients 
% Requiring 
2.58 3.33 3.33 3.33 3.33 3.33 
ARU Treatment 
Total ARU 
73 185 275 366 457 548 
Patients 
% Outpatient 
0.66 0.66 0.66 0.66 0.66 0.66 
Treatment 
% Inpatient 
0.34 0.34 0.34 0.34 0.34 0.34 
Treatment 
Total 
48 121 181 240 300 359 
Outpatients 
Total 
25 63 94 124 155 186 Inpatients 
Outpatient Visit 
1.29 1.29 1.29 1.29 1.29 1.29 
Frequency 
Inpatient Length 
14.60 14.60 14.60 14.60 14.60 14.60 
of Stay (Days)* 
Total 
Outpatient 62 156 233 310 387 463 
Visits 
Total Inpatient 
365 917 1,367 1,817 2,268 2,718 Days* 
* Includmg all mpatIent days accrued m advance and after temrunatJOn of the study penod. 
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8.3 Projected Antiretroviral Referral Unit Costs 
8.3.1 Cost per Outpatient Visit 
Total variable costs per outpatient visit are presented in Table 8.3. Variable costs per 
outpatient visit are assumed to be independent of total Antiretroviral Referral Unit utilisation 
levels, and remain constant throughout the projection period. Total fixed costs per outpatient 
visit for the projection period are presented in Table 8.4, and total fixed and variable costs are 
presented in Table 8.5. These results are illustrated in Figure 8.3. 
Table 8.3: Variable Costs per Outpatient Visit 














Table 8.4: Fixed Costs per Outpatient Visit 
March 2007 March 2008 March 2009 March 2010 
3,119.22 3,119.22 3,119.22 3,119.22 
Consultant 
6,194.97 6,194.97 6,194.97 6,194.97 6,194.97 2 
Administration 
3,334.61 3,334.61 3,334.61 3,334.61 3,334.61 
Capital 
28,165.74 28,165.74 28,165.74 28,165.74 28,165.74 28,165.74 
General 
6,713.98 6,713.98 6,713.98 6,713.98 6,713.98 6,713.98 Overheads 
Total 
47,528.52 47,528.52 47,5 47,528.52 47,528.52 47,528.52 
Fixed Costs 
Total Outpatient 
62 156 310 387 463 Visits 
Fixed Cost per 
766.59 304.67 2 153.32 122.81 102.65 
Out atient Visit 
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Table 8.5: Total Costs per Outpatient Visit 
March 2005 March 2006 March 2007 March 2008 March 2009 March 2010 
Fixed Cost per 
766.59 304.67 203.99 153.32 122.81 102.65 Outpatient Visit I 
Variable Cost per 
845.75 845.75 845.75 845.75 845.75 845.75 r.. tVisit 
Total Cost per 
1,612.34 1,150.42 1,049.74 999.07 968.56 948.40 Outpatient Visit 
Figure 8.3: Projected Year-on-Year Costs per Outpatient Visit, 






-: 1000,00 __ Variable Cosls per Visit 
"" .....t.--Fixed Costs per Visit '" • • • • • • ~ 800,00 
~ 
___ TetllCosls per lIisit y 
~ 
"" = 60000 








2005 2006 2007 2008 2009 2010 
8.3.2 Cost per Inpatient Day and per Inpatient Admission 
Total variable costs per inpatient day and per inpatient admission are presented in Table 8.6. 
Variable costs per inpatient day and per inpatient admission are assumed to be independent of 
total Antiretroviral Referral Unit utilisation levels, and remain constant throughout the 
projection period. Total fixed costs per inpatient day and per inpatient admission for the 
projection period are presented in Table 8.7, and total fixed and variable costs are presented in 
Table 8.8. These results are illustrated in Figures 8.4 and 8.5. 
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Table 8.6: Variable Costs per Inpatient Day and per Inpatient Admission 
Variable Cost per Inpatient Length of Variable Cost per 
Inpatient Day Stay~llY& Inj!atient Admission 
Inpatient-
186.48 14.60 2,722.60 Specific 
Medical Officer 
73.01 14.60 1,065.95 (I) 
Medical Officer 
25.71 14.60 375.37 (2) 
Medical + Surgical 
1.67 14.60 24.38 Supplies 
Total 
286.87 4,188.30 
Table 8.7: Fixed Costs per Inpatient Day and per Inpatient Admission 
t:-a .... 2005 Marcb 2006 March 2007 March 2008 10 
4,678.83 G,678.83 '~.83 8.83 I 4,678.83 4,678.83 (I) 
Consultant 
7,272.35 7,272.35 7,272.35 7,272.35 7,272.35 7,272.35 (2) 
Medical Ward 
37,380.00 37,380.00 37,380.00 37,380.00 37,380.00 37,380.00 Personnel 
Administration 
175.51 175.51 175.51 175.51 175.51 175.51 
Capital 
62,842.31 62,842.31 62,842.31 62,842.31 62,842.31 62,842.31 
General 
98,068.80 98,068.80 98,068.80 98,068.80 98,068.80 98,068.80 Overheads 
Total 
210,417.80 210,417.80 210,417.80 210,417.80 210,417.80 210,417.80 
Fixed Costs 
Total 
240 603 899 1,195 1,491 1,787 Inpatient Days'" 
Fixed Cost per 
876.74 348.95 234.06 176.08 141.13 117.75 Inpatient Day 
Inpatient Length of 
14.60 14.60 14.60 14.60 14.60 14.60 Stay (Days) 
Fixed Cost per 
Inpatient 12,800.42 5,094.69 3,417.24 2,570.79 2,060.43 1,719.14 
Admission 
... Total mpatlent days for March 2005. 
Table 8.8: Total Costs per Inpatient Day and per Inpatient Admission 
March 2005 
March March March 
2006 2009 2010 
876.74 348.9 141.13 117.75 
286.87 286.87 286.87 286.87 
1,163.61 635.79 428.01 404.64 
Fixed Cost per 
12,800.42 5,094.69 2,570.79 2,060.43 1,719.14 In atient Admission 
Variable Cost per 
4,188.30 4,188.30 4,188.30 4,188.30 4,188.30 4,188.30 In atient Admission 
Total Cost per 
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Figure 8.4: Projected Year-on-Year Costs per Inpatient Day, 
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8.4 Sensitivity Analysis 
The projection of costs per outpatient visit, per inpatient day and per inpatient admission 
assumed that all general overhead costs were fixed costs. Under certain circumstances, such 
costs may behave as variable costs, and expand according to demand levels. As an example 
of this phenomenon, this sensitivity analysis assumes that 50% of all general outpatient 
overhead costs are variable by nature, and examines the effects on projected costs per 
outpatient visit. 
Sensitivity analysis results are presented in Table 8.9, Table 8.10 and Table 8.11, and in 
Figure 8.6. Assuming 50% variable general overhead costs, total costs per outpatient visit for 
March 2010 adjust from the original projection level ofZAR 948.40 to ZAR 995.30. 
Table 8.9: Variable Costs per Outpatient Visit (Adjusted) 























Table 8.10: Fixed Costs per Outpatient Visit (Adjusted) 
March 2005 March 2006 March 2007 March 2008 March 2009 March 2010 
Consultant 
3,119.22 3,119.22 3,119.22 3,119.22 3,119.22 3,119.22 
(1) 
Consultant 
6,194.97 6,194.97 6,194.97 6,194.97 6,194.97 6,194.97 
(2) 
Administration 
3,334.61 3,334.61 3,334.61 3,334.61 3,334.61 3,334.61 
Capital 
28,165.74 28,165.74 28,165.74 28,165.74 28,165.74 28,165.74 
Fixed General 
3,356.99 3,356.99 3,356.99 3,356.99 3,356.99 3,356.99 
Overheads 
Total 




62 156 233 310 387 463 Visits 
Fixed Cost per 
712.44 283.15 189.58 142.49 114.14 95.40 
Outpatient Visit 
Table 8.11: Total Costs per Outpatient Visit (Adjusted) 
March 2005 March 2006 March 2007 March 2008 March 2009 March 2010 
Fixed Cost per 
712.44 283.15 189.58 142.49 114.14 95.40 
Outpatient Visit 
Variable Cost per 
899.90 899.90 899.90 899.90 899.90 899.90 
Outpatient Visit 
Total Cost per 
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Figure 8.6: Sensitivity Analysis of Adjusted Year-on-Year Costs per Outpatient Visit, 
March 2005 - March 2010. 
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9. Discussion 
9.1 Epidemiological Resnlts 
9.1.1 Demand for Antiretroviral Referral Unit Services 
The total number of patients on or preparing for HAART in the GF Jooste Catchment Area 
increased by 39.72% between October 2004 (1,853 patients) and March 2005 (2,589 patients). 
Antiretroviral Referral Unit monthly treatment levels varied between 97 patients (November 
2004) and 73 patients (March 2005). Monthly demand for secondary level services, as a 
proportion of patients on or preparing for HAART and attending an antiretroviral clinic within 
the GF Jooste Catchment Area, was observed to range from 4.74% in November 2004 to 
2.58% in March 2005. These results suggest a consistent level of demand for secondary level 
treatment in the early stages of the antiretroviral roll-out. 
9.1.2 Descriptive Patient Characteristics 
A high proportion of patients attending the Antiretroviral Referral Unit during the study 
period were female (77.0% of outpatients; 76.0% of inpatients) and between 26 and 35 years 
of age (44.68%; 54.17%). A high proportion of patients were observed to originate from the 
Site B (26.67%; 27.27%), Guguletu (20.0%; 13.64%), and GF Jooste Hospital (20.0%; 
22.73%) antiretroviral clinics. These results suggest that the need for secondary level 
treatment for patients on or preparing for HAART may be associated with gender, age 
demographic and treatment location. 
Advanced HIY/AIDS infection (WHO Clinical Stage 3 or 4) was recorded for all 
Antiretroviral Referral Unit inpatients. 88.0% of inpatients were classified as Clinical Stage 
4, as opposed to 43.75% of outpatients. In addition, 94.74% of inpatients presented with a 
CD4 count below 200 wmi as compared to 47.73% of outpatients. These results suggest that 
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the need for hospitalisation of patients on or preparing for HAART is related to stage of 
disease advancement and CD4 count. 
9.1.3 Antiretroviral Data 
A high proportion of inpatients (64.0%) and outpatients (68.75%) were receiving 
antiretroviral medication. Outpatients on HAART had generally been receiving antiretroviral 
therapy for longer periods than inpatients on HAART, as indicated by the respective mean 
and median times since HAART initiation. These results suggest that the length of time on 
antiretroviral treatment may be associated with the need for hospitalisation of HAART 
patients, and that secondary outpatient care is frequently required for extended periods after 
HAART initiation. 
A high proportion of inpatients and outpatients on HAART received a combination of 3TC, 
D4T and Efavirenz antiretrovirals (66.67%; 62.5%). 3TC and D4T were the most frequently-
used drugs amongst Antiretroviral Referral Unit patients. As the 3TC, D4T and Efavirenz 
regimen is the primary first-line HAART regimen in the GF Jooste Catchment Area (National 
Department of Health: 2004a), no relationship between specific drug use and the need for 
secondary level treatment can be inferred. 
9.1.4 Length of Stay and Visit Duration 
The mean length of stay for inpatients was 14.60 days. This is higher than prior length of stay 
findings for HN-positive patients at GF Jooste Hospital (Haile: 2000), suggesting advanced 
morbidity and associated treatment requirements amongst inpatients receiving HAART. The 
average outpatient visit duration was 47.37 minutes. This is higher than recorded primary-
level consultation times for both HAART and non-HAART patients (Cleary et al: 2004a), 
suggesting greater diagnostic complexity at the secondary level. This result also provides 
supporting evidence for potential efficiency gains associated with the introduction of 
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secondary level outpatient care for patients on or preparing for HAART, assuming that such 
treatment may reduce the need for subsequent inpatient admissions. 
9.1.5 Patient Diagnoses 
Inpatient and outpatient diagnoses were dominated by infections (55.56%; 49.33%). 
Tuberculosis formed a high proportion of both inpatient (50.0%) and outpatient (43.24%) 
infections diagnoses, suggesting a need for attention to the clinical and health system issues 
raised by (i) the high incidence of tuberculosis in patients on or preparing for HAART and (ii) 
the combined effects of tuberculosis infection and HAART treatment. While antiretroviral 
< 
drug related diagnoses accounted for 24.0% of all outpatient diagnoses, these diagnoses were 
relatively infrequent for inpatients (5.56%), supporting the suggestion that the need for 
secondary treatment of patients on or preparing for HAART is often unrelated to antiretroviral 
. drug complications (Meintjes: 2004b) . 
. 9.1.6 Patient Outcomes 
Antiretroviral Referral Unit patient outcomes suggest high levels of improvement or 
stabilisation as a result of secondary level treatment. The proportions of patient 
improvements and stabilisations are similar for inpatients and outpatients (65.0%; 72.55%), 
suggestive of an efficient inpatient admission triage system. The relatively low share of the 
'no change' outcome for inpatients (15.0%) suggests that most patients may be either 
effectively treated at the secondary level, or are in terminal health decline. 
Patient destinations also suggest a high level of successful treatment for outpatients, with 
88.52% returning to ptimary care. However, the high proportion of outpatients returning for 
follow-up visits (54.1%) suggests the need for ongoing outpatient monitoring and treatment. 
For inpatients, the high proportion of patients referred for continued secondary care (52.17%) 
suggests limited capacity at GF Jooste Hospital, and illustrates the frequent need for extended 
inpatient hospitalisation. 
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9.2 Patient-Specific Cost Results 
9.2.1 Laboratory Testing Costs 
Laboratory testing costs for inpatients and outpatients were dominated by blood testing costs 
(74.98%; 73.0%). These results suggest that blood testing forms a key element of secondary 
level patient treatment, and that the possibility of more efficient methods of blood testing, 
including greater intemalisation of blood testing procedures and analysis, should be 
9.2.2 Imaging and Radiology Costs 
Imaging and radiology costs were primarily accrued by CT Scanning procedures for 
inpatients and outpatients (57.88%; 49.27%). These results support the inclusion of a CT 
Scanner in the proposed Antiretroviral Referral Unit equipment requirements (see Appendix 
B). 
9.2.3 Medication Costs 
Medication costs for inpatients and outpatients were dominated by non-antiretroviral 
antimicrobials (67.8%; 44.33%) and antiretroviral drugs (12.94%; 37.01%). These results 
suggest that the use of non-antiretroviral antimicrobials forms a key element of patient care at 
the secondary level. In addition, these results are compatible with the high levels of infection 
diagnoses amongst inpatients and outpatients. Conversely, the provision of antiretroviral 
drugs was observed to be largely dependent on the availability of patients' primary care 
supplies. 
27 The GF Jooste Laboratory is currently limited to conducting basic laboratory tests, and outsources more 
complex procedures. 
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9.2.4 Medical and Surgical Procedures Costs 
Medical and surgical procedures costs were dominated by ambulatory rather than theatre-
based procedures. Lumbar punctures (42.65%; 26.47%) and upper gastro-intestinal 
endoscopies (30.05%; 30.31%) formed a high proportion of medical and surgical procedures 
costs for inpatients and outpatients. The high proportion of lumbar puncture costs suggests 
that investment in associated equipment ( e.g. manometers) or procedure facilities should be 
explored. The share of upper gastro-intestinal endoscopy costs supports the inclusion of 
associated equipment in prospective Antiretroviral Referral Unit equipment costs (see 
Appendix B). 
9.2.5 Intravenous Fluids 
Intravenous fluids costs were primarily accrued by saline fluids (62.03%). All medication 
provided through intravenous fluids was classified under medication, thereby limiting the 
range of the intravenous fluids category. 
9.2.6 Counselling Costs 
Counselling costs were distributed across a number of different counselling types. The need 
for a range of different counselling services for Antiretroviral Referral Unit inpatients 
suggests the ongoing need for both adaptability and comprehensive training in counselling 
staff at the secondary level. 
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9.3 Costing and Cost-Outcome Results 
9.3.1 Patient-Specific Costs 
Patient-specific costs for Antiretroviral Referral Unit inpatients and outpatients were 
dominated by laboratory testing (21.53%; 35.54%), medical and surgical procedures (15.11 %; 
27.56%), and imaging and radiology costs (12.22%, 26.41%). Medication costs formed a 
relatively low proportion of total patient-specific costs for inpatients and outpatients (10.82%; 
10.5%), suggesting that the treatment of patients on or preparing for HAART is primarily 
dependent on a range of secondary-level infrastructural, equipment and support facilities. The 
high proportion of inpatient-specific consumables costs (37.81%) may be attributed to the 
high cost of intravenous lines (ZAR 101.89 per set). 
9.3.2 Clinical Personnel Costs 
Clinical personnel costs for Antiretroviral Referral Unit inpatients and outpatients were 
dominated by clinician costs. Medical officer costs accounted for a high level of total clinical 
personnel costs for Antiretroviral Referral Unit outpatients (54.72%), while the cost of 
inpatient medical ward clinical personnel formed a high proportion of total inpatient clinical 
personnel costs (51.19%). The relatively low share of nursing costs for outpatients (17.75%) 
suggests that the increased delegation of duties and responsibilities to relatively low-cost 




9.3.3 Overhead Costs 
Outpatient overhead costs are primarily composed of general overhead costs (49.20%), 
followed by medical and surgical supplies (26.37%). Inpatient overhead costs are dominated 
by general overhead costs. Overhead costs per inpatient day are nearly double (1.87) the level 
of overhead costs per outpatient visit, reflecting the higher utilisation of overhead resources 
by inpatients. 
9.3.4 Capital Costs 
Antiretroviral Referral Unit outpatient capital costs are primarily accrued by building and 
medical equipment costs (67.32%; 30.38%). Administrative equipment and staff training 
costs form a relatively low proportion of outpatient capital costs (1.88%; 0.42%). These 
results emphasise the high cost of medical equipment relative to building space, and therefore 
encourage the expansion of building space to house key medical equipment. Antiretroviral 
Referral Unit inpatient capital costs are primarily composed of inpatient medical ward capital 
costs (94.87%), reflecting the low anticipated utilisation of Antiretroviral Referral Unit 
facilities by inpatients. 
9.3.5 Total Cost per Outpatient Visit 
Total costs per outpatient visit are primarily composed of clinical personnel and capital costs 
(33.84%; 28.18%). Overhead costs make up a relatively small proportion of total costs 
(13.65%). These results are in line with prior studies (Cleary et al: 2005), and are indicative 
of the relative importance of these categories to planning, resource allocation and budgeting 
decisions. Total costs per outpatient visit are significantly higher than equivalent findings in 
prior related studies (ibid). This differential may be explained by the existence of excess 
capacity in fixed costs at baseline. 
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9.3.6 Total Cost per Inpatient Day and per Inpatient Admission 
Total costs per inpatient day and per inpatient admission are primarily generated by clinical 
personnel (26.15%), capital (22.5%) and overhead (35.32%) costs. The relatively low share 
of capital costs per inpatient day and per inpatient admission, when compared with capital 
costs per outpatient visit, reflects the use of inpatient medical ward capital facilities as 
opposed to Antiretroviral Referral Unit building and equipment. Total costs per inpatient day 
are in line with findings from previous studies (Haile: 2000). 
While the cost per outpatient visit is therefore currently greater that the cost per inpatient day, 
it should be noted that the total cost per inpatient admission is 10.54 times higher than the 
total cost per outpatient visit, supporting the suggestion that outpatient care represents a more 
efficient use of resources, where it is medically and ethically possible. 
9.3.7 Cost-Outcome Results 
The cost-outcome per successfully-treated outpatient visit is ZAR 2,701.76 as compared to a 
cost per standard outpatient visit of ZAR 1,612.34, representing an increase in costs of 
67.57%. The cost-outcome per successfully treated inpatient day (inpatient admission) is 
ZAR 2,234.13 (ZAR 21,482.03) as compared to a cost per standard inpatient day (inpatient 
admission) ofZAR 1,163.61 (ZAR 16,988.71), representing an increase in costs of91.99%. 
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9.4 Costing Projection Results 
9.4.1 Projected HAART Coverage 
Projected numbers of patients on or preparing for HAART show a month-on-month increase 
from 2,831 patients in March 2005 to 16,443 patients in March 2010 in the GF Jooste 
Catchment Area. This represents an increase of 13,612 patients or a 580.81% increase in 
treatment levels over the projection period. These results suggest that provisional long-term 
antiretroviral coverage targets (National Department of Health: 2003) may have been 
overestimated if treatment expansion occurs at the projected linear rate. 
9.4.2 Projected Antiretroviral Referral Unit Demand 
Assuming a constant level of 3.33% of patients on or prepanng for HAART requiring 
Antiretroviral Referral Unit treatment, the total number of Antiretroviral Referral Unit 
patients is expected to increase from 73 in March 2005 to 548 in March 2010. This represents 
an increase of 475 patients, or a 750.68% increase in Antiretroviral Referral Unit treatment 
levels over the projection period. These results suggest that the secondary level treatment of 
patients on or preparing for HAART is likely to become a key issue for the South African 
health system as the use of antiretrovira1 drugs increases. Projected levels of Antiretrovira1 
Referral Unit patients suggests the need for ongoing expansion of facilities and personnel for 
associated secondary level treatment and care. 
9.4.3 Prospective Antiretroviral Referral Unit Costs 
Total costs per outpatient visit decline from ZAR 1,612.34 in March 2005 to ZAR 948.40 in 
March 2010. This represents a decrease in costs per outpatient visit of ZAR 663.94 or 
41.17%. Similarly, total costs per inpatient day (inpatient admission) decline from ZAR 
1,163.61 (ZAR 16,988.72) in March 2005 to ZAR 404.64 (ZAR 5,907.73) in March 2010, 
representing a decrease in costs of 65.22%. These declines in costs are explained by the 
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economies of scale of Antiretroviral Referral Unit expansion, whereby initial fixed costs are 
spread over an increasing number of inpatients and outpatients28 . These results suggest that 
high initial costs of treatment for both inpatients and outpatients will decrease dramatically 
over the projection period, in line with expectations for programmes with high development 
costs (Johns and Tan Torres: 2005). 
9.4.4 Sensitivity Analysis 
The sensitivity analysis produced a 4.95% increase in the cost per outpatient visit from ZAR 
948.40 to ZAR 995.30. This result suggests that the categorisation of certain overhead costs 
as variable costs does not produce a significant alteration in total costs. 
9.5 Limitations 
9.5.1 General Limitations 
Cost analyses require a significant temporal commitment for successful execution. Data 
collection is frequently dependent on the availability of third parties, while the selection and 
categorisation of key costs requires ongoing assessment and adjustments. In the case of a new 
project, these costs must be determined without the assistance of a costing template or 
associated studies. Such costing studies have been described as 'complex, difficult and time 
consuming to perform' (Beck et al: 2001, p 16). In addition, the resources required to 
perform economic evaluations are themselves scarce, and must therefore be rationed 
appropriately (Drummond et al: 1987). 
28 Amongst other circumstances, economies of scale arise in health care when fixed costs are spread over a larger 
number of units of output, or more efficient use is made of expensive diagnostic equipment (Clewer and 
Perkins: 1998). 
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9.5.2 Demand for Antiretroviral Referral Unit Services 
Total monthly Antiretroviral Referral Unit treatment levels are presented as a proportion of 
patients attending antiretroviral clinics within the GF Jooste Catchment Area. As illustrated 
in Section 5.3.3, patients are occasionally referred to the Antiretroviral Referral Unit from 
clinics outside the GF Jooste Catchment Area, such as the Red Cross Hospital and Groote 
Schuur Hospital. The total proportion of HAART patients in the GF Jooste Catchment Area 
requiring secondary level treatment may therefore have been overestimated. 
9.5.3 Antiretroviral Referral Unit Costs 
9.5.3.1 Data Collection 
Limitations on the availability of appropriate datasets frequently diminish the accuracy of cost 
analysis results. 'Two obstacles that frequently exist include scarcity of resources to perform 
the costing exercise, and the lack or inaccessibility of data' (Beck et al: 2001, p 16). Where 
possible, key primary datasets for this research were sourced directly from GF Jooste 
Hospital. Where this data was unavailable, equivalent prices were sourced from alternative 
costing sources (e.g. the South African Uniform Patient Fee Schedule) or secondary data sets 
(e.g. Cleary et al: 2005). 
9.5.3.2 Translator Costs 
No translator position was included in the Antiretroviral Referral Unit personnel resource 
requirements. Antiretroviral Referral Unit patients were predominantly English-speaking. In 
addition, a number of Antiretroviral Referral Unit clinical and non-clinical personnel were 
multilingual, communicating with patients in English, Afrikaans and Xhosa. These 
circumstances may not apply in other cultural contexts and geographical settings, representing 
a limitation on the rephcabihty of Antiretroviral Referral Unit personnel cost results. 
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9.5.3.3 Medical Ward Costs 
Capital, clinical personnel, and overhead costs for the GF Jooste Medical Ward were included 
in the assessment of Antiretroviral Referral Unit inpatient costs. These costs were included to 
provide a complete representation of all costs associated with the Antiretroviral Referral Unit. 
In practice, these costs are the responsibility of GF Jooste Hospital, and are not directly borne 
by the Antiretroviral Referral Unit. 
9.5.4 Costing Projection Results 
9.5.4.1 Projected HAART Coverage 
The calculation of projected HAART coverage levels for the GF Jooste Catchment Area was 
dependent on a number of assumptions. The extrapolation of HAART coverage levels 
employed a linear projection model, based on prior monthly increases in antiretroviral 
treatment in local antiretroviral clinics. This model assumes that increases in HAART 
treatment levels will continue at the same rate until 2010. HAART coverage levels for 2010 
will have been underestimated if treatment levels increase at an accelerated rate in the future. 
9.5.4.2 Projected Antiretroviral Referral Unit Demand 
The proportion of patients on or preparing for HAART requiring secondary level care for the 
projection period was based on empirical attendance data for the Antiretroviral Referral Unit 
and was assumed to remain constant. Owing to the scale and scope of the AIDS epidemic, 
and the associated challenges to primary level care in diagnosing HW/AIDS at an early stage 
of the disease, it was assumed that a constant proportion of patients on or preparing for 
HAART during the projection period will initiate treatment in a state of advanced 
immunosuppression and require secondary level care. Should a higher proportion of patients 
commence HAART prior to advanced immunosuppression, or the efficacy (or side-effect 
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profile) and effectiveness of antiretroviral treatment improve, Antiretroviral Referral Unit 
demand levels for 20 I 0 may have been overestimated. 
In addition, outpatient visit frequency and the average inpatient length of stay were held 
constant for the projection period. Should efficiency improvements in the secondary level 
treatment of patients on or preparing for HAART occur during the projection period, 
Antiretroviral Referral Unit demand levels for 2010 will have been overestimated. Finally, 
the proportions of patients on or preparing for HAART requiring inpatient and outpatient care 
were held constant for the projection period. This ratio may alter during the projection period 
due to any combination of the above considerations, with associated cost effects. 
9.5.4.3 Prospective Antiretroviral Referral Unit Costs 
The decline in costs per outpatient visit, per inpatient day and per inpatient admission over the 
projection period is dependent on the categorisation of fixed and variable costs. Should any 
fixed costs categories require additional resources over time, or should they prove to be 
variable costs in practice, this decline will have been overestimated. The effect of fixed and 
variable cost categorisation on total costs is described in Section 8.3.3. 
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10. Conclusion 
10.1 Use of Results 
10.1.1 Policy Utilisation 
This research has attempted to determine the costs of secondary level treatment and care of 
patients on or preparing to initiate HAART. The measurement of these costs is designed to 
provide policymakers with information on the hidden or downstream costs of widespread 
antiretroviral treatment. This study therefore aims to assist in the determination of the scope, 
scale, pace and spatial distribution of the national antiretroviral roll-out. Walker notes that in 
the context of HIV/AIDS treatment, 'cost information, both measures of cost and cost-
effectiveness, serves as a critical input into the processes of setting priorities and allocating 
resources efficiently' (2003, p 4). In South Africa, Cleary et al note that 'there is very limited 
data on the expenditure required by the public health system to meet the needs of HIV-
positive people across the continuum of care' (2004b, pi). 
10.1.2 GF Jooste Hospital Utilisation 
The assessment of the current and prospective costs of the Antiretroviral Referral Unit is 
designed to contribute to the budgeting and planning processes at GF Jooste Hospital, in 
preparation for an era of widespread HAART utilisation in the GF Jooste Catchment Area. 
Data on the resource requirements for full Antiretroviral Referral Unit operation, as well as 
current and prospective data on the total costs of treating patients on or preparing for HAART 
at the secondary level, may be utilised by hospital administrators and clinicians in resource 
allocation decisions. 
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10.1.3 Further Utilisation 
The determination of the key costs required for the secondary level treatment of patients on or 
preparing for HAART is designed to provide support to academic research into technical and 
allocative efficiency in the South African health system. In addition, this research may be 
utilised by other secondary hospitals in South Africa in order to assess the resources required 
for the introduction of an Antiretroviral Referral Unit. While local infrastructural 
considerations may require variations on the GF Jooste model, this evaluation may 
nonetheless serve as a template for the delivery of specialised secondary care. 
More broadly, estimates of the costs of secondary level treatment of patients on or preparing 
for HAART may provide a useful input into the assessment of the health system and 
macroeconomic effects of HNIAIDS in South Africa. Finally, the results of this research 
may be used as a guideline for other countries intending to introduce HAART through their 
public health systems. 
10.2 Research Recommendations 
10.2.1 Immunosuppressiou Levels 
Advanced research into the current and prospective levels of patients on or preparing for 
HAART and in a state of advanced immunosuppression is required to gain further insights 
into the potential future demands on secondary level hospitals. A full assessment of the 
morbidity status of new HAART patients will assist in the planning and development of 
related services. 
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10.2.2 Voluntary Counselling and Testing 
The increased costs of improved and expanded Voluntary Counselling and Testing (VCT) 
services for earlier detection of HNIAIDS may be offset by savings in treatment and care 
costs at the secondary level. Ongoing research into the affordability and development of 
widespread VCT services is may assist in generating improvements in patient response to 
antiretroviral treatment, thus reducing both morbidity levels and associated downstream costs. 
10.2.3 Antiretroviral Drugs 
The increased costs associated with the manufacture and distribution of 'safer' antiretroviral 
drugs (e.g. drugs less likely to cause hyperlactataemia or lactic acidosis) may be offset by 
savings in treatment and care costs at the secondary level. Research into the additional costs 
and potential savings of the use of improved first-line antiretroviral regimens is required for 
the successful advancement of the antiretroviral roll-out. 
10.2.4 HAART Treatment and Opportunistic Infections 
The high level of diagnosis and treatment of patients on or preparing for HAART for 
infections such as tuberculosis suggests the need for further research into the appropriate 
primary-level investigation and treatment of such patients. In particular, research on 
interventions designed to expedite the diagnosis of tuberculosis at the primary level may 
assist in reducing associated morbidity and the need for secondary level referral. 
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10.3 Policy Recommendations 
10.3.1 Provision of Secondary Level Facilities and Associated Funding 
The provision of appropriate funding for the development of key facilities at the secondary 
level to support the HAART roll-out should be included as an integral part of the health care 
budgeting and planning process at the meso, provincial, and national levels. The provision of 
adequate secondary-level support for widespread antiretroviral therapy is essential to the 
success of both individual HAART treatment and the roll-out process as a whole. 
""'" 
10.3.2 Sustain ability and Durability ofmV/AIDS Expenditure 
Health system interventions, including the antiretroviral roll-out, may frequently concentrate 
resources on the provision of short-term consumable items. The importance of sustainable 
and durable investments in the health system is supported by the findings of this study. Only 
through parallel and complementary investment in clinical personnel, buildings and medical 
equipment can the South African health system hope to advance and progress through the 
challenges posed by the AIDS epidemic. 
10.3.3 Distributive Equity Opportunities 
The allocation of funds based on vertical interventions, such as the antiretroviral roll-out, 
should aim to achieve distributive equity where possible. In this way, the historical under-
funding of specific facilities, services and geographical areas, such as those represented by GF 
Jooste Hospital, may be redressed whilst simultaneously responding to immediate treatment 
requirements. Increased expenditure on disadvantaged facilities may be combined with a 
focus on long-term capital investment to produce significant improvements in the quality of 
services offered to disadvantaged areas. 
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10.3.4 System-Wide Approach 
The implementation of vertical interventions such as the antiretroviral roll-out should consider 
the future of the health system as a whole. Only through an integrated approach to health care 
interventions can future economic and burden of care shocks be avoided. The need for a 
system-wide approach to the treatment and care of HNIAIDS, rather than a limited and 
potentially blinkered focus on primary level initiatives, is recommended. 'The successful 
implementation of the ARV treatment programme depends on a broadly strengthened health 
system' (Guthrie and Hickey: 2004, p 159). 
10.4 Concluding Remarks 
This study has provided a detailed economic analysis of the secondary level treatment of 
patients on or preparing for HAART through a case study of the proposed GF Jooste 
Antiretroviral Referral Unit. A full cost analysis, a cost-outcome description and a projection 
of prospective costs per outpatient visit, per inpatient day and per admission were produced. 
It is to be hoped that a detailed picture of the demands placed on secondary hospitals through 
the treatment of patients on or preparing for HAAR T has been created. 
This study does not seek to undermine or question the affordability and viability of the 
antiretroviral roll-out. Rather, it attempts to provide additional information on the true costs 
to the South African health system of this ambitious project. In this way, the findings of this 
study are designed to assist in the successful implementation of widespread antiretroviral use. 
This study seeks to provide evidence that widespread vertical or primary-level interventions, 
such as the roll-out of antiretroviral therapy, have the potential to create a wide range of 
hidden and downstream costs. In assessing the viability of specific health interventions, it is 
of paramount importance that policymakers consider their impact at all levels of the health 
system. This conclusion should be borne in mind by pressure groups, lobbying campaigns 
and other stakeholders in the antiretroviral roll-out Only through the comprehensive 
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assessment of resource requirements across the health system can vertical interventions be 
fully audited and resources distributed appropriately. 
The ongoing applicability of the results of this research are dependent on a wide range of 
variables, many of them both unpredictable and beyond the scope of this study. The ultimate 
scale of the AIDS epidemic, the success of the antiretroviral roll-out and the ongoing use of 
antiretrovirals in HN I AIDS treatment, and the ongoing need for secondary level treatment 
of patients on or preparing for HAART are contingent on a range of secondary and currently 
indefinite factors. However, based on the status quo and assuming ceteris paribus, the 
resources required for the treatment of patients on or preparing for HAART may be expected 
to grow in proportion to the scale and scope of the antiretroviral roll-out. 
Ultimately, the aim of this study is to inform the resource allocation decisions of the South 
African health system, both within and beyond the context of the AIDS epidemic and 
antiretroviral treatment, and to illustrate the key role of economics in the assessment of health 
care interventions. Only through the appropriate use of the tools of economic evaluation can 
a socially and individually just and fair distribution of scarce resources be achieved. 
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This research presents a partial economic evaluation of the current and anticipated impact of 
widespread antiretroviral treatment on the secondary hospital system in South Africa. The 
evaluation encompasses the treatment and care of HIV -positive inpatients and outpatients on 
or preparing for highly active antiretroviral therapy (HAART) at the secondary level. This 
study was conducted based on analysis of the Antiretroviral Referral Unit at GF Jooste 
Hospital during March 2005, and utilises a combination of current and retrospective data sets. 
Current and projected fixed and recurrent costs per outpatient visit, inpatient day and inpatient 
admission are presented. A range of epidemiological results are also analysed. 
Epidemiological results suggest that most patients requiring Antiretroviral Referral Unit care 
are women (77.0% of outpatients; 76.0% of inpatients) with a mean age of 35.9 years for 
outpatients and 34.0 years for inpatients. The most commonly used antiretroviral regimen 
was 3TC+D4T+Efavirenz for both inpatients (66.67%) and outpatients (62.5%) currently 
receiving HAART. Diagnoses were dominated by infections (49.33% of outpatient 
diagnoses; 55.56% of inpatient diagnoses) rather than antiretroviral drug-related complaints 
(24.0%; 5.56%). Successful treatment outcomes were recorded for a high share of patients. 
Costing results describe the share and composition of capital, overhead, clinical personnel and 
patient-specific costs per outpatient visit, per inpatient day and per inpatient admission. 
Capital and clinical personnel costs accounted for high shares of total costs for both inpatients 
(22.50%; 26.15%) and outpatients (28.18%; 33.84%). Detailed analysis of patient-specific 
costs revealed laboratory testing and medical and surgical procedures as key cost drivers. 
Cost projections indicate a decline in costs per outpatient visit and per inpatient day (and 
admission) over time due to economies of scale, ceteris paribus. Cost-outcome results 
indicate that treatment costs rise considerably when effectiveness of treatment is considered. 
A range of research and policy recommendations based on these findings are presented. 
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GF Jooste Antiretroviral Referral Unit, March 2005. 
Instructions to Attending Clinicians: Please provide all details for (current and new) HAART 
outpatients attending the GF Jooste Antiretroviral Referral Unit during the study period 1 - 31 March 
2005. Please be as comprehensive as possible in stating all patient costs. Space has been provided for 
explanatory comments where necessary. Please print clearly and legibly. Thank you for your time. 
Section 1: Patient Details 
Patient Folder Number: 
Date of Birth: 
Patient Gender: o Male o Female 
Patient Type: o New o Existing 
Referred From: 
WHO HIV / AIDS Clinical Stagel : o 1 o 2 o 3 04 
Most Recent CD4 Count: 
Date of Most Recent CD4 Count: 
HAART Status: o Receiving HAART o Preparatory Period 
Date ofHAART Initiation: 
HAART Regimen Type: o Regimen 1 o Regimen 2 o Other 
Drug Content of HAART Regimen: 
Name of Attending Antiretroviral Clinic: 
Section 2: Treatment Outcome 
Was a Definitive Diagnosis Made? 0 Yes o No o Unknown 
Patient Response to Treatment: 0 Improved 0 Deteriorated o Stabilised 
o No Change o Unknown o Died 
Destination of Patient: o Hospice 0 Tertiary o Primary 
o Inpatient o Other 
If Other, Please State: 
I See attached document for a description of the WHO Clinical Staging System. 
II 
Section 3: Patient Visit Record 
Date of Visit: 
Duration of Visit: 
Other Attending Clinician(s): 
Diagnosis 
.... 
Section 4: Laboratory Tests 
Test Type 
* If other than GF Jooste Hospital. 



















Section 5: Imaging and Radiology 
~·······-------=I-m-a-g-:-in-g-T-v-. p-e----------,--=L-o-ca-t--:-io-n-*:---r-----=C:-o-m~m-e-n-t-s----
Section 6: Medication 
Medicine Type Quantity Duration Comments 
Section 7: Medical and Surgical Procedures 
Procedure Type Location * Comments 
* J f other than OF Jooste HospItal. 
IV 
Section 8: Medical and Non-Medical Consumables and Other Costs 
Type Comments 
Section 9: Other Illnesses or Medical Conditions and Associated Medication (i.e. Tuberculosis) 
Illness or Medical Condition Medication Comments 
Section 10: Additional Information 
Section 11: Attending Clinician Details 
Name: 




Data Capture Form for the Costing ofHAART-Related Treatment and Care for Inpatients. 
GF Jooste Antiretroviral Referral Unit, March 2005. 
Instructions to Attending Clinicians: Please fill in all details of (current and new) HAART inpatients 
treated by the GF Jooste Antiretroviral Referral Unit during the study period 1 - 31 March 2005. 
Please be as comprehensive as possible in recording all patient costs. Space has been provided for 
explanatory comments where necessary. Please print clearly and legibly. Thank you for your time. 
Section 1: Patient Details 
Patient Folder Number: 
Date of Birth: 
Patient Gender: o Male o Female 
Patient Type: o New [] Existing 
Referred From: 
Admission Date: 
Discharge Date (Estimate if Unknown): 





WHO HIV I AIDS Clinical Stagel : o 1 o 2 o 3 o 4 
Most Recent CD4 Count: 
Date of Most Recent CD4 Count: 
HAART Status: o Receiving HAART o Preparatory Period 
Date ofHAART Initiation: 
HAART Regimen Type: o Regimen 1 o Regimen 2 o Other 
Drug Content of HAART Regimen: 
Name of Attending Antiretroviral Clinic: 
2 See attached document for a description of the WHO Clinical Staging System. 
VI 
I 
Section 2: Laboratory Tests 
I 
Test Type Date Location* Comments 
Section 3: Imaging and Radiology 
Imaging Type Date Location* Comments 
* If other than GF Jooste HospItal. 
VII 
Section 4: Medication (Including Locally-Provided HAART and Other Medication) 
Medicine Type Daily Dosage Start Date End Date 
Section 5: Medical and Surgical Procedures 
I 
Procedure Type Date Location* Comments 
i-----.. 
I 
* If other than GF Jooste Hospital. 
VIII 
Section 6: Physiotherapy 
.. 
Reason for Physiotherapy Date Location'" Comments 
Section 7: Social Worker Counselling or HIV / AIDS Counselling 
Reason for Counselling Date Location* Comments 
Section 8: Discharge Medication 
Medicine Type Date Quantity Comments 
* If other than GF ]ooste Hospital. 
IX 
Section 9: Medical and Non-Medical Consumables and Other Costs 
Type Date Comments 
Section 10: Other Illnesses or Medical Conditions and Associated Medication (i.e. Tuberculosis) 
Illness or Medical Condition 
Section 11: Treatment Outcome 
Was a Definitive Diagnosis Made? 
Patient Response to Treatment: 
Destination of Patient: 
If Other, Please State: 









D No D Unknown 
D Deteriorated D Stabilised 
D Unknown D Died 
D Tertiary D Primary 
D Other 
Data Capture Form for the Costing ofHAART-Related Treatment and Care. 
GF Jooste Antiretroviral Referral Unit, March 2005. 
Instructions to Staff: Please fill out this time diary based on your work and experience in the 
Antiretroviral Referral Unit (ARU) at GF Jooste Hospital during the period 14 18 March 2005. This 
form relates to the treatment and care of ARU patients only. Full confidentiality will be preserved 
in the analysis and use of this information. Thank you for your participation. 
Section J: Daily Time Allocation 












* Telephone ConsultatIOn Service. 
Section 2: Additional Information 
Section 3: Staff Member Details 
Position: o Consultant o CMO o MO 
o Nurse o Clerk o Other 






B.1 Proposed GF Jooste Antiretroviral Referral Unit Building 
Admissions Area: Space for a clerk's desk and a storage and filing area. Telephone line 
for admissions clerk. 
Waiting Area: Space for soft furnishings for patients. Wheelchair access and 
general access to ablution facilities. 
Offices: Five clinician offices. Capacity for conversion into consultation 
rooms if required. Telephone line in each office. 
Consulting Rooms: Five consulting rooms. Space for desk and examination couch in 
each consulting room. Consulting rooms may serve multiple roles 
for consultations, minor procedures, and counselling. Each room 
equipped with capacity for one blood pressure cuff and one 
diagnostic set (opthalmoscope and otoscope) anchored to the wall. 
Procedure Room: One procedure room. Large enough to allow for bronchoscopy, 
gastroscopy and colonoscopy equipment. Requires scope fittings, 
resuscitation facilities and washing facilities. 
Ablution Facilities: Three ablution facilities. Male patient toilet and washing facilities. 
Female patient toilet and washing facilities. Staff toilet. 
Sluice Room: One sluice room. 
XII 
B.2 Proposed GF Jooste Antiretroviral Referral Unit Equipment 
Table B.1: Antiretroviral Referral Unit Medical Equipment 
Medical Equipment Unit Price Quantity Total Price 
Automated Observation Machine with BP Cuff and Pulse Oximeter 21,000.00 1 21,000.00 
Blood Pressure Cuff 340.00 5 '1,700.00 
!Bronchoscopy Unit 450,000.00 1 450,000.00 
CT Scanner' 3,000,000.00 1 150,000.00 
!Diagnostic Sets (Opthalmoscope and Otoscope) 456.0C 5 2,280.00 
Gastro-Intestinal Endoscopy Unit 130,000.OC 1 130,000.00 
Reflex Hammer 89.0C 10 890.00; 




Stethoscope 10 540.0C 
iI'rucut Biopsy Gun 300. I 300.00 
Ultrasonic Nebuliser for Sputum Induction 2,244.78 1 2,244.78 
X-Ray Board 549.0C 6 3,294.0C 
Total - - 765,598.7~ 
Table B.2: Antiretroviral Referral Unit Non-Medical Equipment 
Non-Medical Equipment Unit Price Quantity Total Price 
Cable to Link Computer to NHLS Laboratory 456.61 4 1,826.44 
Cell Phone 3600.00 I 3,600.00 
iChair 650.00 2C 13,000.00 
Computer 5500.00 3 16,500.00 
Computer 5500.00 3 16,500.001 
Desk 784.0( II 8,624.00 
Printer 450.0C 3 1,350.00 
(Total - - 44,900.44 
3 For CT Scanner equipment costs, prospective Antiretroviral Referral Unit utilisation was estimated at 5.0% of 
total hospital utilisation, based on consultation with Dr. Graeme Meintjes. 
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B.3 Antiretroviral Referral Unit Medical and Surgical Supplies, March 2005 
Table B.3: Antiretroviral Referral Unit Medical and Surgical Supplies, March 2005 
Medical and Surgical Supplies Amount Unit Price Total Price 
Alcohol Medical Swabs 250.0C 0.08 20.00 
Blood Culture Bottles 15.0C 2.05 30.7L 
!Dressing Packs 30.0C 6.04 181.09 
Elastoform Bandages 4.0C 28.3 113.48 
iGauze Swabs 40.00 0.2 10.96 
!General Purpose Hypodermic Promex Needles 120.00 0.31 36.90 
~Iides 30.00 20.50 615.00 
1.00 90.00 90.00 
Lavender Blood Collecting Vacutainer Tubes 250.00 1.80 450.40 
Linen Savers 30.00 1.60 47.95 
Non-Sterile Examination Gloves 20.00 13.65 
Non-Sterile Latex Gloves 150.00 0.74 111.18 
Sputum Jars ~ 7.00 700.00 Sterile Single Use Stitch Cutter Blade 72.90 729.00 
Surgeons Latex Gloves 60.00 0.74 44.47 
Tegaderm/Opsite (small) 60.00 1.05 63.00 
Winged Infusion Sel 25.00 3.1" 78.001 
Total - - 3,997.47 
XIV 
C.l Prior Antiretroviral Referral Unit Utilisation Levels 
Prior Antiretroviral Referral Unit utilisation levels were based on the time period October 
2004 to March 2005 inclusive. Total Antiretroviral Referral Unit patients include all 
inpatients and outpatients treated by the Antiretroviral Referral Unit. The average monthly 
percentage of patients on or preparing for HAART requiring Antiretroviral Referral Unit 
treatment was used for the projection period, and is presented in Table c.l. 
Table C.I: Prior Antiretroviral Referral Unit Utilisation Levels 
Month 
Antiretroviral Referral Patients on or Preparing % Antiretroviral Referral 
Unit Patients forHAART* Unit Patients 
October 76 1989! 
lNovember 97 2046 
lDecember 62 2184 
~anuary 66 2358 
lFebruary 83 2589 
lMarch 73 2831 
[Average - -
* PatJents prepanng for HAART were mcluded by addmg the total number of new starts In each 
succeeding month to each preceding month. 
C.2 Ratio of Inpatients to Outpatients 
The ratio of inpatients to outpatients for the projection period was based on the corresponding 
ratio for the study period. Derivation of this ratio :is presented in Table C.2. 
Table C.2: Ratio ofInpatients to Outpatients 
March 2005 (Total) March 2005 (%) 
Outpatients 48 65.75 
Inpatients 25 34.24 








D.l Determination of Clinical Personnel Costs and Allocation Factors 
Antiretroviral Referral Unit clinical personnel costs per outpatient visit, per inpatient day and 
per inpatient admission were determined based on data from the clinician data capture forms 
(see Appendix B). Data on the weekly level and distribution of clinical personnel time is 
presented in Table D.I. 
Table D.I: Antiretroviral Referral Unit Clinical Personnel Weekly Time Distribution (Minutes) 
Consultant (I) Consultant (2) Medical Officer (1) Medical Officer (2) 
Outpatient 120 155 750 180 
Contact 
Inpatient 180 180 330 780 
Contact 
TCS* 75 80 110 45 
Research 0 0 0 195 
Analysis 0 0 0 0 
Meetings 210 90 330 330 
Clerical 0 90 0 225 
Other 0 30 0 0 
Total 
585 625 1520 1755 
* Telephone ConsultatIOn ServIce. 
Data on the level and distribution of Antiretroviral Referral Unit clinical staff time was 
combined with monthly salary data to produce total Antiretroviral Referral Unit clinical staff 
costs4• This figure was then allocated to inpatient and outpatient care according to the 
distribution of inpatient and outpatient contact time (see Table D.I). The derivation of total 
monthly clinical personnel costs for outpatients and inpatients is presented in Table D.2. 
4 Time spent on TCS was excluded from the detennination of cost per outpatient visit, cost per inpatient day and 
cost per inpatient admission, on the assumption that TCS patients were not treated at the Antiretroviral 








· Table D.2: Derivation of Antiretroviral Referral Unit Monthly Clinical Personnel Costs 
Consultant Consultant Medical 
I 
Medical Nursing 
(1) (2) Officer (1) Officer (2) Sister i 
Monthly Salary 
32,109.6\ 5\,892.42 26,567.63 30,633.49 8,079.87 
Daily Salary* 
1,605.48 2,594.62 1,328.38 1,531.67 403.99 
Hourly Salary** 
229.35 370.66 189.77 218.81 57.71 
i 
I Salary per 3.82 6.18 3.16 3.65 0.96 Minute 
Total Weekly 
510 545 1,710 1,410 1,560*** 
Minutes 
Total Weekly 
1,949.51 3,366.83 5,408.41 5,142.05 1,500.55 
Cost 
Total Monthly 
7,798.05 13,467.32 21,633.64 20,568.20 6,002.19 Cost** 
% Outpatient 
40.0 ! 46.0 19.0 70.0 100.0 J Time 
Total I 
Outpatient 3,119.92 6,194.97 4,110.39 14,397.74 6,002.19. 
I Monthlv Cost 
I 
% Inpatient 
60.0 i 54.0 81.0 30.0 0.0 I 
Time 
I Total Inpatient 
4,678.83 7,272.35 17,523.25 i 6,170.46 I 0.00 i Monthly Cost i 
* Assumes 20 workmg days per month. 
** Assumes 7 working hours per day. 
*** Based on average medical o.fficer weekly minutes. 
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